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ABSTRACT 
CD8+ T Cell Antiviral Activity: Mechanism of Induction and the Suppression of 
Emerging Feline Immunodeficiency Virus Strains. 
(May 2004) 
Anagha Phadke, 
B.S., University of Bombay, Mumbai, India; 
M.S., University of Bombay, Mumbai, India 
Co-Chairs of Advisory Committee: Dr. Ellen Collisson 
        Dr. Rita B. Moyes 
 
 
 
 In the present studies, the essential role of inducer cells for the induction of 
soluble anti-viral activity against feline immunodeficiency virus (FIV) was investigated. 
Induction of suppression of FIV replication was found to not strictly require autologous 
cells and was probably not FIV specific. Suppression was maximum when the inducer 
cells and the effector CD8+ T cells were in contact with each other, suggesting a 
potential role for membrane antigen interactions and/or cytokines in the induction 
process. Additionally, flow cytometry analysis demonstrated a significant increase in the 
percentage of CD8+ B7-1+ T cells in the peripheral blood of chronically FIV infected 
cats as compared with uninfected cats.   
 Examination of the FIV V3-V4 envelope sequences from PBMC, lymph nodes 
and spleen from six cats chronically infected from three to six years with the molecular 
clone of FIV-PPR did not demonstrate viral variants specific for the tissues examined, 
emphasizing the critical role of the initial diversity and virulence of the infecting virus 
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inoculum. Additionally, in vitro CD8+ T cell antiviral activity demonstrated by four of 
the six cats could have led to the control of virus replication in vivo, resulting in the 
uniform viral variants observed.  
Infection of specific pathogen free cats with FIV-TX53, an FIV isolate that 
belongs to an emerging subtype more closely related to FIV clade B, demonstrated an 
acute stage infection characterized by lymphoadenopathy and a viral dose dependent 
decline of CD4+/CD8+ T cell ratios below 1 by 11 weeks post infection. Interestingly, an 
expansion of CD8βlow population of CD8+ T cells was observed in the infected cats.  
The soluble antiviral activity generated from inducer T cell stimulated CD8+ T 
cells from FIV-A-PPR infected cats also suppressed in vitro replication of the emerging 
FIV-TX53 and FIV-TX078 isolates. This is the first report demonstrating that the CD8+ 
T cell antiviral activity is inter-clade effective among FIV strains. As the success of a 
FIV vaccine could be hampered by occurrence of highly divergent viral variants in the 
fields, the exploitation of this innate, soluble anti-FIV activity could contribute to the 
design of novel, safe and complementary anti-FIV therapeutic strategies. 
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CHAPTER I 
 
INTRODUCTION 
 
FELINE IMMUNODEFICIENCY VIRUS  
FIV genome organization 
Feline immunodeficiency virus (FIV), previously called feline T–lymphotropic 
virus, was first isolated in 1986 from a Petaluma cat in California with an AIDS like 
disease (Pedersen et al., 1987). FIV is classified as a member of the lentivirus genus of 
the Retroviridae family because it resembles lentiviruses, such as human 
immunodeficiency virus and simian immunodeficiency virus, in virion morphology, 
tropism for T lymphocytes and for cells of the monocyte, macrophage lineage, Mg2+-
dependent reverse transcriptase activity and persistent infection in the host (Olmsted et 
al., 1989b; Pedersen et al., 1987; Talbott et al., 1989; Yamamoto et al., 1989). Since its 
discovery, FIV has been recognized as a common pathogen worldwide in both domestic 
and wild cats such as panthers, pumas, lions and bob cats (Olmsted et al., 1992; 
Yamamoto et al., 1989). The similarity of FIV infection in cats to HIV infection in 
humans, makes it a suitable small animal model for evaluating the potential of certain 
antiviral compounds, (Bisset et al., 2002; North and LaCasse, 1995), approaches for 
experimental vaccination  (Jarrett et al., 1990; Pu et al., 2001; Yamamoto et al., 1991) 
and pathogenesis of lentivirus induced immunodeficiency (Yamamoto et al., 1988).  
                                                 
  This dissertation follows the style of Virology. 
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Although FIV is similar to primate lentiviruses, including HIV, in its biologic 
activities in the host, its genetic organization and gene regulation are more similar to the 
lentiviruses of the ungulates (Olmsted et al., 1989a; Sparger et al., 1992; Talbott et al., 
1989; Thompson et al., 1994a). The FIV genome is composed of two copies of about 
9,400 bp of single stranded RNA, has three long open reading frames encoding the 
group associated antigen, polymerase and envelope proteins and several short ORFs 
encoding the regulatory proteins, such as vif, rev and ORF-A (Phillips et al., 1990; 
Talbott et al., 1989). The gag gene is initially translated to yield a precursor polyprotein 
of about 50kDa that is subsequently cleaved to yield the functionally mature matrix, 
capsid and nucleocapsid proteins (Bendinelli et al., 1995; Elder et al., 1993; Steinman et 
al., 1990). The pol gene overlaps the gag gene by 109 nucleotides, is in a -1 reading 
frame with respect to that of gag gene and is translated as a gag-pol fusion polyprotein 
by ribosomal frameshifting (Morikawa and Bishop, 1992). This polyprotein is then 
cleaved to yield protease, reverse transcriptase, dUTPase and integrase (Elder et al., 
1992; Elder et al., 1993).  The primary translation product of the FIV env gene is 
processed through proteolytic cleavage into the surface protein and the transmembrane 
protein (TM) (gp40) (Verschoor et al., 1993). Pancino et al. (1993b) have identified nine 
variable (V) regions throughout the FIV env protein. The first two lie in the leader 
region, which is also the first coding exon of the rev gene and because of proteolytic 
processing are not present in the mature env protein. Variable regions V3 through V6 are 
found in the SU, and variable regions V7 through V9 occur in the TM. The env 
glycoprotein plays a key role in determining viral tropism, mediates membrane fusion 
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involved in virus penetration and syncytium formation, and it contains linear and 
conformational epitopes (de Ronde et al., 1994) against which humoral immune 
responses are induced by the host. The V3 region of the SU, in addition to the 
ectodomain of the TM glycoprotein (Vahlenkamp et al., 1997) has been found to be 
responsible for the tropism of FIV for Crandell feline kidney (CRFK) cells (Siebelink et 
al., 1995b; Verschoor et al., 1995). Macrophage tropism is dictated by the V3 and V4 
regions of the env gene (Vahlenkamp et al., 1999). The V3 region also contains a linear 
neutralization domain (de Ronde et al., 1994; Lombardi et al., 1993b) that is involved in 
the neutralization of CRFK cell adapted FIV strains while V4 and V5 regions were 
found to be necessary for FIV neutralization in feline thymocytes (Siebelink et al., 
1995a). Cell culture adapted strains of FIV are able to use CXCR4 to facilitate cell 
fusion mediated through the V3 region (Willett et al., 1997b; Willett et al., 1997c). The 2 
long terminal repeats (LTRs) of FIV, like those of maedi-visna virus, but unlike HIV, 
have strong basal promoter activity at least in certain cell types and are only poor 
transactivators (Miyazawa et al., 1992; Sparger et al., 1992). Studies on the regulatory 
genes of FIV have indicated similar roles for these proteins in FIV and HIV replication. 
The viral infectivity factor (vif) gene, essential for FIV replication in lymphocytes and 
macrophages, encodes a regulatory protein that is necessary for cell free virus 
dissemination to new target cells from the initial site of infection (Lockridge et al., 1999; 
Shacklett and Luciw, 1994). Rev is necessary for stabilization and transport of unspliced 
and singly spliced viral mRNA from the nucleus to the cytoplasm (Kiyomasu et al., 
1991; Phillips et al., 1992; Tomonaga et al., 1993b). Orf-A, a tat-like gene encodes a 
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viral transactivator necessary for productive FIV replication in primary peripheral blood 
mononuclear cells (PBMC), primary feline T cells and feline T cell lines (de Parseval 
and Elder, 1999; Phillips et al., 1990; Sparger et al., 1994; Tomonaga et al., 1993a; 
Waters et al., 1996). However, unlike other lentiviral transactivators, it requires 
additional LTR elements, such as ATF for transactivation (Chatterji et al., 2002). 
  
FIV env diversity 
 Molecular clones of FIV have been derived from the Petaluma strain designated 
as FIV-34TF10 and FIV-14 (Talbott et al., 1989), from the PPR strain designated as 
FIV-pPPR (Phillips et al., 1990), from  the Japanese strain FIV-TM2 designated as 
pTM219 (Miyazawa et al., 1989), from the Netherlands strain (Siebelink et al., 1992), 
from the Glasgow strain FIV-GL8 designated as FIV-GL8414 (Hosie et al., 2000) and 
from the FIV-NCSU1 strain designated as JSY3 from North Carolina (Yang et al., 1996). 
Under experimental conditions three FIV isolates have shown to consistently induce 
fatal immunodeficiency disease: Subtype A virus FIV NCSU1 (English et al., 1994) 
which has been molecularly cloned (Yang et al., 1996), and rapidly passaged versions of 
FIV subtype C  and B isolates (Bachmann et al., 1997; Diehl et al., 1995b). 
Sequences within the env gene are least conserved among the FIV isolates 
(Pancino et al., 1993b; Sodora et al., 1994). Five distinct clades of FIV (A-E) have been 
identified with 15-30% variability in env amino acid sequence although a majority of 
viruses identified belong to either clade A or clade B (Bachmann et al., 1997; Elder et 
al., 1998; Sodora et al., 1994). Recent studies on FIV diversity in our laboratory have 
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provided evidence that FIV isolates from free-roaming cats in Texas, forming a distinct 
cluster as compared to other clades, may have evolved from FIV clade B (Weaver et al., 
2004). Although these cats were present with various clinical abnormalities, such as skin 
lesions, lymphoid hyperplasia and presence of roundworms and tapeworms at necropsy, 
the acute stage of the disease caused by these FIV TX isolates has not been previously 
studied. For a vaccine to be effective, selection of vaccine challenge strains that are most 
representative of field isolates is essential. Hence studying the disease course manifested 
by the isolates belonging to the newly emerging subtype is essential for identifying new 
more virulent strains. 
Different mechanisms have been put forward to explain HIV-1 env evolution in 
vivo, including recruitment of latently infected CD4+ cells and T cell activation, positive 
selection of variants as a result of viral escape from specific host defenses, such as CTLs 
and also the effect of negative forces (Casado et al., 2001). Moreover non-selective 
mechanisms, such as random drift, founder effects, bottlenecking and Muller’s ratchet 
and compartmentalization and selection of variants with env glycoproteins optimally 
adapted to locally expressed receptors (Casado et al., 2001; Wong et al., 1997), have also 
been found to be associated with env variation. In addition to this, the error prone 
reverse transcriptase with a high rate of HIV turnover also contributes to accumulation 
of point mutations in the HIV genome (Preston et al., 1988).  
Studies regarding the evolution of FIV env gene over time have yielded 
contrasting results. Most of the studies carried out with naturally infected cats 
demonstrate very close similarity (99.3% or 98%) between the viral variants obtained 
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from different tissues of the same animal (Nishimura et al., 1996; Siebelink et al., 1992). 
Sodora et al. (1994) found that intra-cat diversity of env sequences from naturally 
infected cats was approximately half of that reported for sequence variation of HIV-1 
from humans. A degree of sequence similarity among different proviral clones is unusual 
for lentiviruses, which in general show much more sequence variation, especially in the 
env gene. An exception to this are studies by Greene et al. (1993) that have shown that 
the rate of change of FIV was 3.4 x 10-3 nucleotide substitutions per site per year for the 
env gene and less than 10-4 nucleotide substitutions per site per year for the gag and pol 
genes, values that were similar to those found that for HIV-1. In this study though, virus 
isolates derived from the same cat were more highly related to each other than to isolates 
from other cats (10-12% env variation). Since these studies have been carried out using 
naturally infected cats, the length of the time that the cats had been infected, in addition 
to the diversity in the infecting virus inoculum, early target cells or tissues in the host, 
expansion of the fittest genotype (s) in each tissue and induction of host immune 
response would contribute to the evolution of viral variants.  
In order to determine the temporal genetic variation in the env gene, it is 
necessary to start with a homogenous population of virus that can be studied for both, 
viral evolution within a host and generation of tissue specific variants by eliminating 
factors, such as the initial mixed inoculum of viral variants that differ in cellular tropism. 
An important feature of the FIV model system is the availability of molecular clones 
that, after transfection into cells in culture, give rise to infectious virions (Hosie et al., 
2002; Miyazawa et al., 1991; Phillips et al., 1990; Siebelink et al., 1992; Talbott et al., 
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1989). Hence the fate of a single FIV clone can be determined, as it replicates over time 
in the infected host. Relating the biological properties of such populations to the 
genomic structure of the molecular clone, from which they were derived, may reveal 
changes in amino acids required for enhanced pathogenicity and altered tropism of the 
virus.  
Kohmoto et al. (2003) demonstrated that the molecular clone of FIV TM2 could 
be transmitted across the mucosal epithelium without broadening of cell tropism or lack 
of variation in the V3- V5 env region at 4 weeks post infection (p.i.). Infection with a 
molecular clone of FIV Petaluma FIV-F14 yielded viral variants from the peripheral 
blood of two infected cats at 135 weeks p.i. (Hosie et al., 2002), which had altered cell 
tropism as compared to the parental clone used for infection. Dean et al. (1999) found 
that experimental inoculation of cats with molecular clones of FIV-PPR and Petaluma 
(FIV-34TF10 and FIV-14) yielded viral variants in the bone marrow in 3 cats infected 
with FIV-34TF10, in the lymphoid tissues of 1 cat infected with FIV-14 and 2 cats 
infected with FIV-PPR at 23 weeks p.i. by heteroduplex mobility assay. However studies 
that screened for the presence of FIV viral variants among different tissues of 
chronically infected cats initially experimentally infected with a molecular clone of FIV 
have not been reported.  
  
FIV receptors and tropism 
 Although FIV infects CD4+ T cells, FIV does not use the CD4 molecule as a 
primary receptor or coreceptor (Hosie et al., 1993; Norimine et al., 1993; Willett and 
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Hosie, 1999). CD9 was identified as a putative receptor for FIV but later was found to be 
required for virus release from the cells rather than virus entry (de Parseval et al., 1997; 
Willett et al., 1997a). The primary isolates of FIV (which have been passaged 3-10 
times) can be propagated only in cultures of fresh mitogen stimulated PBMC, dendritic 
cells, thymocytes, macrophages or IL-2 dependent T cell lines (Brown et al., 1991; Dean 
et al., 1996; Dow et al., 1999; English et al., 1993). FIV can also infect a range of CD4- 
cell types including feline monocytes and macrophages, B cells and cells of the neuronal 
lineage, such as primary cultures of astrocytes and microglia, but neither 
oligodendrocytes nor neurons (Willett and Hosie, 1999). The primary and tissue culture 
passaged isolates of clade A and the laboratory adapted isolates of strain B share usage 
of the CXCR4 receptor, the co-receptor for the entry of HIV into cells, for env-mediated 
fusion and productive infection of cells (Egberink et al., 1999; Frey et al., 2001; 
Poeschla and Looney, 1998; Richardson et al., 1999; Willett et al., 1997c). It is not yet 
clear if this receptor serves as a primary receptor or the co-receptor for FIV infection. A 
40kDa protein (distinct from CXCR4) has also been thought to play a role in FIV-PPR 
infection and cell-adapted FIV-34TF10 molecular clone’s SU interaction with primary 
feline T cells (de Parseval and Elder, 2001). FIV-PPR was also found to infect CRFK 
cells using CXCR4 but at very low levels, while FIV-34TF10 was shown to use cellular 
heparans, in addition to CXCR4, for infection of adherent cells, such as CRFK cells, 
G355-5 feline glial cells, human Jurkat T cells, HeLa cells and interleukin (IL)-2 
independent feline lymphoma cells 3201(de Parseval and Elder, 2001; Lerner and Elder, 
2000). CXCR4 was also found to mediate the entry of FIV-Petaluma into astrocytes, 
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maybe contributing to dementia in the later stages of FIV infection (Nakagaki et al., 
2001). Detection of mRNA messages for CCR5, CXCR4, and CCR3 in various feline 
tissues of the reproductive tract, large intestine and PBMC also point to the possible role 
of multiple chemokine receptors in the entry of FIV (Caney et al., 2002; Kovacs et al., 
1999). Infection of primary human PBMC and macrophages in vitro by two different 
strains of FIV, FIV Petaluma and V1-CSF was inhibited by antibodies to human 
CXCR4, CCR5 and CCR3 (Johnston and Power, 1999; Johnston and Power, 2002). 
Experimental FIV infection of cyanomolgous macaques resulting in loss of CD4+ T cells 
and weight loss has also been shown (Johnston et al., 2001). The capacity of both 
primate and non-primate lentiviruses to interact with chemokine receptors suggests 
common determinants in the pathogenesis of these viruses that could facilitate cross-
species transmission. 
  
Mode of transmission of FIV 
 The major mode of transmission of FIV is thought to be via bite wounds 
(Yamamoto et al., 1989). FIV has been demonstrated in the saliva of naturally or 
experimentally infected cats (Yamamoto et al., 1989) and can also be isolated from the 
blood, serum, plasma, cerebrospinal fluid of naturally and experimentally infected cats 
by tissue culture methods (Yamamoto et al., 1988). Venereal transmission from infected 
males to females though never been clearly documented experimentally, is thought to be 
possible since replication competent FIV in cell free and cell associated forms could be 
detected in the semen of domestic cats (Jordan et al., 1995). At least some strains of FIV 
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can be transmitted vertically from mother to offspring in utero, post natally via milk, and 
potentially also during parturition, thus paralleling perinatal HIV transmission in humans 
(O'Neil et al., 1995; O'Neil et al., 1996). Virus strains representing three clades of FIV 
(A, B and C) can be experimentally transmitted across vaginal, rectal and oral mucosa 
by either cell associated or cell-free virus (Bishop et al., 1996; Bucci et al., 1998a; Bucci 
et al., 1998b; Burkhard et al., 1997; Gebhard et al., 1999; Moench et al., 1993; Obert and 
Hoover, 2000a; Obert and Hoover, 2000b; O'Neil et al., 1996).  
 
Disease caused by FIV 
FIV causes a disease syndrome in cats similar to that caused by HIV in humans. 
The clinical phases of FIV infection parallel those of HIV (Pedersen, 1992): 1) an acute 
phase characterized by a burst of viral replication, flu like illness, lymphadenopathy, and 
progressive decline in CD4+  T lymphocytes  with a reduction in the CD4+/CD8+ T cell 
ratio, 2) a prolonged asymptomatic phase with viral downregulation and a continued 
decline of CD4+ T cells and 3) a terminal phase characterized by immunologic 
abnormalities, increase in the viral load, wasting, hematologic suppression and clinical 
immunodeficiency with opportunistic infections. 
Both FIV and HIV infection have a well-defined first stage of disease. The 
primary phase of infection is characterized by varying degrees of fever, diarrhea, 
gingivitis, conjunctivitis, uveitis, jaundice, secondary bacterial sepsis, neutropenia (often 
associated with a mild to moderate leucopenia), and generalized lymphadenopathy. The 
fever and other clinical signs persist from a few days to several weeks before 
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disappearing (Barlough et al., 1991; Callanan et al., 1992; Yamamoto et al., 1988). The 
severity of the primary signs of disease varies with age (George et al., 1993). When FIV-
Petaluma strain was used for infection, the most persistent lymphadenopathy developed 
in newborn kittens while young adult cats (8-12 months of age) developed a much less 
pronounced transient lymphadenopathy and lymphadenopathy was not observed in aged 
cats (7.5-11.5 years of age), in spite of their more rapid rate of progression to the next 
stages of the disease. Similarly, the severity and duration of neutropenia decreased with 
increasing age (George et al., 1993). During the early acute phase of FIV infection, the 
inversion of the CD4+/ CD8+ T cell ratio is compounded by a sharp increase in 
lymphocytes expressing the feline CD8 marker (fCD8). This expanded subset which 
displays reduced expression of the fCD8 marker (fCD8low) and increased levels of 
major histocompatibility complex (MHC) class II antigens (Willett et al., 1993). In 
addition to quantitative changes in lymphocyte phenotype, qualitative dysfunction of B- 
and T- lymphocytes has been reported for FIV infection. The onset of immunodeficiency 
is marked by reduced responsiveness of feline PBMC to in vitro T- cell and B-cell 
mitogens (Siebelink et al., 1990; Torten et al., 1991), decreased interleukin-2 (IL-2) 
production (Lawrence et al., 1995; Siebelink et al., 1990), and hypergammaglobulinemia 
attributable to elevated IgG levels (Ackley et al., 1990).  In addition, there is a 
significant increase in IL-1, IL-6 and tumor necrosis factor production (Lawrence et al., 
1995). Thus, as shown in HIV-infected humans, FIV produces a significant perturbation 
of cytokine production that may contribute to the immune dysfunction. 
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After the initial signs of clinical illness associated with primary FIV infection 
have subsided, the infection usually remains clinically inapparent for prolonged periods 
of varying duration during which the virus can be isolated from the blood (Yamamoto et 
al., 1988). The asymptomatic phase is followed by a phase characterized by persistent 
generalized lymphadenopathy (PGL), including vague signs of illness, such as recurrent 
fevers, anorexia, weight loss or nonspecific behavioral changes (Pedersen, 1992; 
Yamamoto et al., 1989). Chronic secondary or opportunistic infections are absent at this 
stage. Half of the clinically ill cats brought to the veterinarian are present in the next 
stage i.e. the ARC (AIDS-related complex)-like stage of the disease. Cats are presented 
with chronic secondary infections of the oral cavity, upper respiratory tract and other 
body parts, but not with opportunistic infections. The agents causing these infections 
include other feline viruses, bacteria, fungi, protozoa and parasites (Bendinelli et al., 
1995; Pedersen, 1992). Weight loss of about 20%, chronic diarrhea, chronic stomatitis 
and gingivitis, chronic respiratory disease, chronic skin infections, chronic enteritis PGL, 
hematologic abnormalities (anemia, leukopenia, neutropenia, lymphopenia) have also 
been observed (Bendinelli et al., 1995; Pedersen, 1992; Yamamoto et al., 1989). Most, if 
not all, cases diagnosed as ARC progress to feline AIDS (FAIDS) after variable time 
intervals. Cats suffer from secondary infections listed above, opportunistic infections 
and to a lesser extent from neurologic and neoplastic disorders during the FAIDS stage 
(5 to 10% of clinically ill FIV infected cats) (Bendinelli et al., 1995; Hutson et al., 1991; 
Yamamoto et al., 1989). 
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While the usual natural course of FIV infection is observed over several years, 
strains that are associated with accelerated clinical immunodeficiency can be generated 
by in vivo passage of plasma from cats in acute phase of FIV infection (Diehl et al., 
1996; Diehl et al., 1995b). This has been observed with an FIV strain belonging to the 
subtype C designated CABCpadyOOC (FIV-C-PGammer). This isolate rapidly killed 
two-thirds or more of the kittens infected intravenously at <12 weeks of age. Viremia 
detected in the plasma of the infected kittens was higher than that described for either 
acute HIV or SIV infection (Diehl et al., 1995b).  
 
ANTIVIRAL ACTIVITY AGAINST LENTIVIRUSES 
Role of antibodies 
 Antiviral response to FIV infection in cats includes both humoral and cell-
mediated immunity. The antibodies to the capsid (p24) and env proteins appear between 
4 and 6 weeks p.i. in cats infected with FIV. The timing of appearance of the antibodies 
to either capsid or env varies depending on the virus strain used and the route of 
infection (Avrameas et al., 1993; Burkhard et al., 2001; Egberink et al., 1992; Hosie and 
Jarrett, 1990; Rimmelzwaan et al., 1994). Major B cell epitopes have been mapped to 
SU glycoprotein, the TM env glycoprotein (Avrameas et al., 1993; de Ronde et al., 1994; 
Pancino et al., 1993a) and the gag region (Lombardi et al., 1993a). Tozzini et al. (1993) 
found that active production of neutralizing antibodies was evident about 5-6 weeks p.i., 
which reached a plateau 3 to 4 months later and persisted throughout the prolonged 
observation period. Peptides derived from the principal immunodominant domain (PID) 
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(Pancino et al., 1995) found in the FIV env TM region are recognized by 100% of the 
FIV- infected cat sera (Avrameas et al., 1993).   
 
CD8+ T cell mediated antiviral activity 
 Cellular immune responses mediated by CD8+ T cells determine whether a 
person infected with HIV-1 develops AIDS and are often implicated in the maintenance 
of long-term asymptomatic state.  During HIV infection, CTLs are thought to play a key 
role in preventing progression to the AIDS stage. The presence of CTLs has been 
inversely correlated with viral load in HIV infected individuals and hence thought to 
play a key role in maintaining the asymptomatic state in HIV infected individuals 
(Cohen and Fauci, 1996). Persistent CD8+ T cell depletion experiments in SIV infected 
animals, demonstrated an increased SIV viral load, in the absence of CD8+ T 
lymphocytes (Cohen and Fauci, 1996). This indicated that the CTLs were important in 
maintenance of the viral load at a steady state and thus in controlling SIV infection.  
FIV specific CTLs have been detected in the peripheral blood of cats 
experimentally infected with FIV-GL8, as early as 2 weeks p.i. (Beatty et al., 1996), in 
cats chronically infected with the FIV-Petaluma strain (Song et al., 1992; Song et al., 
1995) and in cats mucosally infected with either FIV-A-PPR or FIV-B-2542 at 9 weeks 
p.i. (Burkhard et al., 2001). As the disease progressed following FIV-GL8 infection of 
cats, the CTLs were found to reside predominantly in the lymph nodes and spleen up to 
one year p.i., but were not detected in the peripheral blood (Beatty et al., 1996). This is 
in contrast to the presence of CTLs in chronic FIV-Petaluma infection of cats (Song et 
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al., 1992; Song et al., 1995) and HIV infection where the CTLs persist into the 
asymptomatic period (Rinaldo et al., 1995; Walker et al., 1987) .  
In contrast to the cytotoxic activity, CD8+ T cells suppress viral replication 
leaving the HIV infected cells intact. The non-cytolytic function of CD8+ T lymphocytes 
was first described about 17 years ago by Dr. Jay Levy (Walker et al., 1986). CD8+ T 
cell antiviral response is thought to be mediated, at least in part by the so called soluble 
CD8 antiviral factor (CAF) which lacks identity to known cytokines and chemokines 
such as interleukin (IL)-2 to IL-12, IL-16, Interferon-α, β, γ, TNF-α,  TNF-β, TGF-β, 
granulocyte-macrophage-colony stimulating factor (GM-CSF), RANTES, MIP-1 α,  
MIP-1 β, MCP-1, 3, GRO-α,  GRO-β, leukemia inhibitory factor, lymphotactin, IP-10, 
granzymes A, B, granulysin, protegrins, histatins and defensins, TNF-1 receptors- I and 
II and sFas (Levy, 2003). This antiviral activity was not HLA restricted (Mackewicz et 
al., 1998; Walker et al., 1991a). The antiviral response mediated by CAF has been 
identified very early in primary infection, before the appearance of anti-HIV antibodies, 
is associated with higher CD4+ T cell counts, decreased viral loads, improved clinical 
status and long term-nonprogression (Levy et al., 1996). Non-cytotoxic responses of 
CD8+ T lymphocytes, a type of innate immunity, could be more important than the 
cytotoxic responses in controlling certain viral infections (Levy, 2001). 
A similar kind of immune response involving non-cytolytic CD8+ T cells which 
suppressed replication of FIV in target cells in vitro, in a non-MHC restricted manner 
was seen in naturally or experimentally FIV infected cats (Bucci et al., 1998b; Choi et 
al., 2000b; Flynn et al., 1999; Hohdatsu et al., 2000; Jeng et al., 1996). The CD8+ T cell 
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antiviral activity against FIV-Petaluma and FIV-GL8 could also be demonstrated in 
blood and lymph nodes of cats vaccinated with whole inactivated virus prepared from 
the FIV-Petaluma strain (Flynn et al., 1999). This CD8+ T cell antiviral activity was 
found to be mediated through cell-cell contact between effector cells (CD8+ T cells) and 
target cells (either PBMC or feline T cell lines, such as MYA-1 and FCD4E cells) or in 
part by a soluble factor (Bucci et al., 1998b; Choi et al., 2000b; Flynn et al., 1999; 
Hohdatsu et al., 1998). Human MIP1-α and not SDF1-α was able to suppress FIV-PPR 
replication in feline PBMC (Choi et al., 2000b).  The CD8+ T cell antiviral activity acted 
by inhibiting mRNA transcription during the virus life cycle and could be detected by 
Flynn et al. (1999) during the acute phase only or by others during the asymptomatic 
chronic phase and the symptomatic phase of FIV infection (Choi et al., 2000b; Hohdatsu 
et al., 1998; Jeng et al., 1996). Cats with high levels of FIV suppression in the thymus 
and blood had low virus loads in the primary and secondary lymphoid tissues (Crawford 
et al., 2001). As in humans and primates, virus load was inversely correlated with the 
strength of the FIV suppression among individual cats (Bucci et al., 1998a).  In another 
study, the CD8+ T cell antiviral activity was also found to inversely correlate with 
plasma viremia and CD4+ T cell counts (Hohdatsu et al., 2003). This antiviral activity 
could be detected as early as 1-week p.i. with FIV-GL8 strain, even before the CTL 
activity which was demonstrated at 4 weeks p.i (Flynn et al., 2002). Thus, both CTL and 
non-cytotoxic antiviral activity appeared before the humoral immune response in FIV 
infection indicating that this may be a part of the host’s innate response.  
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Phenotypes of cells involved in the CD8+ T cell mediated antiviral activity 
Following experimental infection of cats with the NCSU1 isolate of FIV, the 
CD8+ T effector cells responsible for non-cytolytic suppression of FIV replication were 
found to have the activation phenotype characterized by reduced surface expression of 
the CD8β-chain (CD8α+βlow) and L-selectin (CD62L), as well as an increased 
expression of CD44, CD49d and CD18 (Bucci et al., 1998b; Gebhard et al., 1999). 
However, the correlation between the CD8+ T cell anti-FIV activity and the presence of 
the unique CD8α+βlow phenotype in cats has been controversial. In neonatal cats infected 
with FIV NCSU1-JSY3, molecular clone, the antiviral CD8+ suppressor cells emerged 
during the acute infection in the blood and thymus and were found to be the predominant 
CD8+ phenotype in the blood and the lymph nodes during chronic infection (Crawford et 
al., 2001). Bucci et al. (1998b) have also shown that the unique CD8α+βlow phenotype 
was responsible for suppression of FIV NCSU1 in acute and long-term asymptomatic 
infection of cats. In contrast to these studies, both CD8hi and CD8lo T cell subpopulations 
prepared from PBMC of FIV-GL8 infected cats were shown to suppress FIV replication 
in vitro (Flynn et al., 2002). Supporting the latter study, Hohdatsu et al. (2003) found no 
correlation between CD8α+βlow or CD8α+β- T cells counts and anti-FIV activity in 
experimentally or naturally infected cats.  
CD8+ T cells that mediate the anti-HIV activity have been characterized by an 
activated phenotype expressing HLA-DR and /or CD28 markers and to correspond to 
CD29+/CD45RA- memory cells (Landay et al., 1993). Copeland et al. (2002) have 
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shown that stronger CAF activity was observed for CD8+ T cells expressing the 
activation markers CD38+ or CD38+HLA-DR+.  
Although the phenotypes characterizing the CD8+ T cells involved in the 
antiviral activity are known, the physiological stimulus and the cells required for their 
stimulation and induction remain a mystery. Recent studies have shown that dendritic 
cells enhanced the non-cytotoxic CD8+ T cell anti-HIV activity in vitro which was 
mediated primarily by production of IL-15 by the mature dendritic cells (Castelli et al., 
2003). Few studies point to the role of costimulatory molecules, such as B7 in enhancing 
the CD8+ T cell antiviral activity. Barker et al. (1999) demonstrated that while both the 
B7-1 and B7-2 costimulatory molecules could deliver a signal sufficient to increase 
CD8+ T cell antiviral activity, it was the B7-2 molecule on macrophages that enhanced 
CD8+ T cell suppression of HIV replication. Although studies by Tompkins et al. (2002) 
have shown significant numbers of B7-1+ CD4+ and B7-1+ CD8+ T cells in both blood 
and lymph nodes of FIV-infected cats with B7-2+ T cells for the most part being 
restricted to lymph nodes, the role of B7-1 in the induction of CD8+ T cells mediating 
anti-FIV activity has not been demonstrated.  
 
Lack of specificity at the effector and inducer phase of control of virus replication 
CD8+ T cell mediated antiviral activity has been demonstrated in HIV-infected 
chimpanzees (Castro et al., 1991), SIV-infected monkeys (Ennen et al., 1994; Kannagi et 
al., 1988), HIV-infected baboons (Locher et al., 1999) and FIV-infected cats (as 
mentioned earlier), suggesting that this natural antiviral response is common in lentivirus 
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infections. CD8+ T cell mediated antiviral activity in HIV and FIV infection has 
however, been found to be non-specific at the effector phase of control. Thus, Walker et 
al. (1991b) demonstrated that CAF is not virus specific and could suppress replication of 
wide variety of lentiviruses, such as HIV-1, HIV-2 and SIV strains. This antiviral 
response has also been shown to reduce LTR transcription of murine and avian 
retroviruses (Copeland et al., 1995). CD8+ T cells of African green monkeys inhibited 
HIV-1 replication in human CD4+ T cells (Ennen et al., 1994) while CD8+ T cells of 
SIV-infected sooty mangabeys inhibited the replication of HIV-2, SIV-1 (SIVsmm-7) and 
HIV-1 (LAV) (Powell et al., 1990). Furthermore, CD3+CD8+ T cells of HIV-1 IIIB 
infected chimpanzees were shown to inhibit replication of HIV-1 strains IIIB, MN and 
RF in vitro (Husch et al., 1993).  In addition, requirement for a specific HIV antigen or 
the virus itself for stimulation of CD8+ T cells to mediate the antiviral activity has also 
not been found to be necessary. Supporting this, the anti-HIV activity has been 
demonstrated from CD8+ T lymphocytes of HIV-uninfected, healthy individuals, CD8+ T 
cell clones derived from HIV-uninfected individuals, CTLs from HIV-1 uninfected 
individuals and even from cord blood (supposed to contain only naïve CD8+ T cells) 
from HIV-uninfected neonates (Bagasra and Pomerantz, 1993; Hsueh et al., 1994; 
Kootstra et al., 1997; Liu et al., 2003; Mackewicz et al., 1997; Rosok et al., 1997). 
Additionally, the CD8+ T cell antiviral activity was found to be effective against 
heterologous FIV isolates such as FIV-Petaluma, FIV-GL8 and FIV-PPR belonging to 
the FIV clade A (Choi et al., 2000b; Flynn et al., 1999). However, effective CD8+ T cell 
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antiviral activity has not yet been demonstrated to afford cross-clade protection in FIV 
infection of cats. 
 
 OBJECTIVES 
In our earlier studies, reproducible production of non-cytotoxic anti-FIV activity 
of CD8+ T lymphocytes, from cats in the asymptomatic stage of FIV infection, was 
maximally achieved in vitro with effector cells stimulated by FIV-PPR strain infected 
inducer T cells rather than mitogen (Choi et al., 2000b). Extending on earlier work the 
objectives of this dissertation were to: 
 Determine the cells that could be used as inducer cells for the stimulation of the 
CD8+ T cells responsible for suppression of FIV replication in vitro  
 Determine the phenotypes of the inducer cells and fresh PBMC with respect to 
B7, MHC class I or MHC class II, CD4 and CD8 expression 
 Examine the kinetics of the induction process to determine the optimal days for 
generating the CD8+ T cell generated anti-FIV activity in vitro 
 Determine effect of the CD8+ T cell antiviral activity generated from CD8+ T 
cells of FIV-PPR infected cats, on the suppression of the newly isolated FIV TX 
strains 
 Examine the pathogenesis of newly emerging TX isolates and compare the acute 
stage of the disease course with that described for other FIV isolates 
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 Examine the presence of viral evolution and tissue specific env variants that may 
have arisen in the cats after three to six years of infection with the FIV-PPR 
molecular clone  
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CHAPTER II 
 
THE ROLE OF INDUCER CELLS IN MEDIATING SOLUBLE ANTI-VIRAL 
ACTIVITY AGAINST FELINE IMMUNODEFICIENCY VIRUS BELONGING 
TO DIFFERENT SUBTYPES* 
 
INTRODUCTION 
Feline Immunodeficiency virus (FIV) is a T-lymphotropic lentivirus in the family 
Retroviridae (Pedersen et al., 1987). Natural or experimental FIV infection of cats 
results in a transmissible AIDS-like disease, similar to that observed with human 
immunodeficiency virus (HIV) infection in  humans (Pedersen et al., 1989; Yamamoto et 
al., 1988). FIV causes a transient acute illness characterized by fever, lymphadenopathy, 
neutropenia and neurologic problems that may recur following latency, resulting in 
clinical illness and immunosuppression (Pedersen et al., 1989; Yamamoto et al., 1988). 
The degree of acute clinical disease is dose-dependent on the infecting inoculum 
(Hokanson et al., 2000). Phylogenetic analysis have separated FIV strains into five 
distinct phylogenetic clades designated A to E, based on 15-30% variability in the 
envelope (env) amino acid sequence although the majority of viruses identified to date 
belong to either clade A or clade B (Bachmann et al., 1997; Elder et al., 1998; Sodora et 
al., 1994). However, recent phylogenetic analyses of Texas FIV isolates demonstrated 
                                                 
* “Reprinted from Virology, 320, Anagha P. Phadke, In-Soo Choi, Zhongxia Li, Eric Weaver, Ellen W. 
Collisson, The role of inducer cells in mediating in vitro suppression of feline immunodeficiency virus 
replication, 63-74, Copyright (2004), with permission from Elsevier”. 
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that these isolates that were closely related to clade B isolates, formed a unique cluster 
distinct from the other clades (Weaver et al., 2004). 
 CD8+  T cells are a critical component of cellular immune protection against HIV 
infection in humans. CD8+ T lymphocytes control HIV, simian immunodeficiency virus 
(SIV), and FIV infection through both cytotoxic (CTL) and non-cytotoxic mechanisms 
(Appay et al., 2000; Barker, 1999; Barouch and Letvin, 2001; Blackbourn et al., 1994; 
Brinchmann et al., 1990; Charaf et al., 1993; Choi et al., 2000b; Flynn et al., 1999; Furci 
et al., 2002; Geiben-Lynn et al., 2001; Hohdatsu et al., 2000; Jeng et al., 1996; Kannagi 
et al., 1988; Le Borgne et al., 2000; Mackewicz et al., 1994; Pollack et al., 1997; Powell 
et al., 1990; Song et al., 1992; Walker, 1993; Walker et al., 1986; Yang et al., 1997). 
Non-cytotoxic responses of CD8+ T lymphocytes, a type of innate immunity, may be 
more important than the cytotoxic responses in controlling certain viral infections (Levy, 
2001). The non-cytotoxic antiviral response seen in certain HIV-infected individuals 
involves suppression by CD8+ T cells of HIV replication in peripheral blood 
mononuclear cells (PBMC), monocyte-derived macrophages and acutely or naturally 
infected CD4+ T cells (Barker et al., 1998; Brinchmann et al., 1990; Levy et al., 1996). 
This CD8+ non-cytotoxic antiviral response is thought to be mediated, at least in part, by 
an undefined secreted CD8 antiviral factor (CAF) (Clerici et al., 1996; Levy, 2001; Levy 
et al., 1996). Such non-cytotoxic activity is not HIV-specific, not species specific, not 
MHC restricted and is identified immediately after acute HIV infection (Clerici et al., 
1996; Levy, 2001; Mackewicz et al., 1998; Walker et al., 1991a). The antiviral activity 
was broadly cross-reactive, as CD8+ T cells from individuals infected only with HIV-1 
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suppressed the replication of diverse strains of HIV-1 and HIV-2, as well as SIV 
(Walker et al., 1991b). The levels of CD8+ T cell anti-HIV responses have been 
correlated with CD4+ T cell counts and the absence of infection in individuals repeatedly 
exposed to HIV and in HIV infected, long-term survivors (Blackbourn et al., 1996; Furci 
et al., 2002; Gomez et al., 1994; Landay et al., 1993; Levy, 2001; Mackewicz et al., 
1991; Stranford et al., 1999). In contrast, Copeland et al. (1997) did not find any 
correlation between the extent of CD8+ T cell mediated suppression and clinical stage of 
infection or CD4+ T cell counts in HIV-1 infected individuals. 
 CD8+ T cell-mediated suppression of FIV replication has been described by 
several groups, although the mechanisms of activation and conditions for viral 
suppression vary with the methodologies (Bucci et al., 1998a; Choi et al., 2000b; 
Crawford et al., 2001; Flynn et al., 1999; Flynn et al., 2002; Hohdatsu et al., 2000; 
Hohdatsu et al., 1998; Hohdatsu et al., 2002; Jeng et al., 1996). Furthermore, in vivo 
reduction of FIV load has been correlated with a strong CD8+ T cell mediated anti-FIV 
activity (Bucci et al., 1998a; Crawford et al., 2001; Unpublished data from our 
laboratory). Mitogen stimulated non-cytolytic T cells capable of suppressing the 
replication of Glasgow8 isolate of FIV (FIV-GL8) represented the first detectable anti-
viral immune response in cats following FIV-GL8 infection (Flynn et al., 2002). In our 
earlier studies, reproducible production of non-cytotoxic anti-FIV activity from CD8+ T 
lymphocytes, from cats in the asymptomatic stage of FIV infection, was maximally 
achieved in vitro with effector cells stimulated by FIV-PPR strain infected inducer T 
cells rather than mitogen (Choi et al., 2000b).  
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Whereas a number of studies have attempted to characterize the CD8+ T cells 
responsible for generating lentivirus suppression (Bucci et al., 1998b; Flynn et al., 2002; 
Gebhard et al., 1999; Landay et al., 1993; Toso et al., 1995; Zanussi et al., 1996) or have 
focused on characterizing the CD8+ T cell antiviral activity (Geiben-Lynn et al., 2001; 
Mosoian et al., 2000), there is little known about the physiologic stimulus, that activates 
the effector CD8+ T cells to generate suppressing activity. Previous reports suggested 
that HIV infection or a potential exposure to the virus was needed for the CAF activity 
(Levy et al., 1998; Walker et al., 1991b). However, the fact that the CD8+ T cell antiviral 
response has been observed in asymptomatic HIV infected individuals (Blackbourn et 
al., 1996; Brinchmann et al., 1990; Hsueh et al., 1994; Mackewicz et al., 1991; Toso et 
al., 1995), HIV exposed but uninfected individuals (Furci et al., 2002; Levy et al., 1998; 
Stranford et al., 1999), healthy HIV-naïve individuals (Bagasra and Pomerantz, 1993; 
Kootstra et al., 1997; Rosok et al., 1997), as well as in FIV infected and uninfected cats 
(Choi et al., 2000b) suggests that mechanisms involved for the induction of this antiviral 
response are not virus specific.  
Since the CD8+ T cell antiviral activity seems to be non-specific with respect to 
HIV in humans or FIV in cats, the elicited immune response would seem to be of an 
innate nature. Both soluble and cellular components contribute to innate immunity 
(Levy, 2001), resulting in a general response of the immune system to an infection 
without specificity for a target antigen. Identifying the conditions leading to the 
induction of this antiviral activity is essential in exploiting this innate control of 
lentiviral infection. Here we report that feline skin fibroblasts (FSF) could be used as 
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inducer cells to mediate the soluble anti-FIV activity and the importance of inducer cell-
effector cell contact in the generation of optimal suppression of FIV replication in vitro. 
Furthermore, in order to determine if this CD8+ T cell antiviral activity could provide 
cross protection against FIV strains from a newly emerging subtype closely related to 
clade B, its effect on the replication of the Texas FIV isolates was also examined. 
 
MATERIAL AND METHODS 
Experimental animals  
Specific, pathogen-free (SPF) cats, purchased from Harlan Sprague-Dawley, 
Madison, WI or Liberty Laboratories, Liberty corner, N.J., were serologically negative 
for feline leukemia virus. Cats were housed in a specific, pathogen-free environment at 
the Laboratory Animal Research and Resources Support Facility (LARR), Texas A&M 
University, College Station. Cats AUO2, AUO3, AWF1, AZV2 and E284 were 
chronically infected with FIV-PPR strain. These cats had been inoculated intravenously 
(i.v.), three to six years previously with 50 to 1250 TCID50 of virus. Cats AUS3, OAE5 
sham inoculated with saline solution were used as negative control cats.   
 
Virus 
FIV-PPR was propagated in feline PBMC from a SPF cat not infected with FIV. 
Additionally, FIV-TX53 (AY139109) and FIV-TX078 (AY139107) strains were 
propagated in PBMC from the feral cat from which it was isolated (Weaver et al., 2004). 
After 7 to 10 days of infection, virus replication was evaluated with an FIV capsid 
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antigen detection enzyme-linked immunosorbent assay (ELISA) (Choi et al., 2000b). 
Supernatants with an optical density (OD) of more than 2.0 were collected and these 
stocks were stored at –80oC. The FIV-PPR virus stock had a titer of 0.5 x 105.1 / ml and 
FIV-TX53 and FIV-TX078 had titers of 0.5 x 106/ ml, determined as described by 
Hokanson (Hokanson et al., 2000).  
 
Cell culture 
Feline PBMC were isolated from EDTA (K3)-treated whole blood by 
Histopaque-1077 (Sigma, St. Louis, MO) density gradient centrifugation (Choi et al., 
2000b). PBMC were cultured as described previously with RPMI 1640 (Gibco BRL, 
Grand Island, N.Y.) supplemented with 10% heat inactivated fetal bovine serum (FBS) 
(Atlas Biologicals, Fort Collins, CO), 50 ug/ml of gentamicin (Gibco BRL, Grand 
Island, N.Y.), 5 x 10-5 M 2-mercaptoethanol (Gibco BRL, Grand Island, N.Y.), 2mM L-
glutamine (Gibco BRL, Grand Island, N.Y.), and 100 U of human recombinant IL-2 (hr 
IL-2) (Gibco BRL, Grand Island, N.Y.) per ml (Choi et al., 2000b). Cells were grown at 
37oC in a humidified atmosphere of 5% CO2.  
 
Continuous culture of feline skin fibroblasts (FSF)  
To develop FSF cell lines, tissues were prepared from skin plug biopsies of 
infected cats AUO2, AUO3, AWF1, AZV2, OLQ5 and uninfected cat OAE5 (Dr. Mary 
Carpino). After five to six passages in culture, the cells were transformed by transfection 
of SV40 T antigen-expressing plasmid DNA (Gift from David Busbee, Department of 
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Veterinary Anatomy, Texas A & M University). The transformed FSF were selected by 
adding geneticin (0.5mg/ml of the medium) (Gibco BRL, Grand Island, N.Y.). The FSF 
were cultured in MEM-alpha supplemented by 10% heat inactivated fetal bovine serum 
(FBS) (Atlas Biologicals, Fort Collins, CO), 2mM L-glutamine (Gibco BRL, Grand 
Island, N.Y.), 20 units/ml of epidermal growth factor (Gibco BRL, Grand Island, N.Y.) 
and 50 ug/ml of gentamicin (Gibco BRL, Grand Island, N.Y.).   
 
Preparation of FIV-PPR infected inducer T cells   
Feline T cells were infected with FIV-PPR strain and irradiated (11,000 rads 
from a 6oCo source provided by the Nuclear Science Center, Texas Engineering 
Experiment Station, College Station) before using as inducer cells for the stimulation of 
effector cells, as previously described (Choi et al., 2000b; Song et al., 1992). Briefly, 
freshly prepared PBMC were stimulated for three days with 5 ug/ml of Concavalin A 
(Con A) (Sigma, St. Louis, MO). The stimulated cells were infected with FIV-PPR for 1 
h at 37oC. The cells were washed and cultured in complete RPMI containing 100 U hr 
IL-2 per ml. After 6 days of incubation, virus replication was monitored using the FIV 
capsid antigen ELISA. These FIV infected cells were cryo-preserved to be used later as 
inducer cells.  
 
Preparation of FSF as inducer cells 
The gene encoding FIV capsid antigen was amplified by PCR from FIV-PPR 
infected T cells using primers synthesized with Bam HI sites and ligated into Bam HI-
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digested Semliki Forest virus vector (SFV) (Gibco BRL, Grand Island, N.Y.) (Phadke et 
al., 2004). The SFV vector RNA was prepared by transcribing in vitro from Spe I-
linearized recombinant vectors and was transfected into FSF using DMRIE-C reagent 
(Gibco, BRL, Grand Island, N.Y.). After 18 hours in complete RPMI medium, the SFV-
capsid expressing FSF were used as inducer cells.  
 
Phenotype enrichment 
 Negative selection for enrichment of CD8+ T from freshly isolated PBMC of FIV-
PPR-infected cats was performed using a combination of panning and magnetic beads. 
Briefly, plastic adherent cells were first removed from fresh PBMC by incubating the 
PBMC in complete RPMI at 37oC in a humidified atmosphere of 5% CO2 for 4 hours. 
The non-adherent cells were washed once in phosphate-buffered saline (PBS). The 
washed cells were then incubated in 1 ml of PBS with 3% FBS containing 500 ul of anti-
feline CD4 monoclonal antibody (CAT30A, gift from Dr. Wayne Tompkins, North 
Carolina State University) and 30 ul of mouse anti-human CD14 monocyte antibody 
(Clone TUK4, Dako, Carpinteria, CA) for 30 minutes at 4oC on a mixer. The cells were 
washed once in PBS, resuspended in 1 ml of PBS with 3% FBS containing M450 
dynabeads that had been coated with goat anti-mouse IgG (Dynal biotech, Great neck, 
N.Y.) and incubated for 30 minutes at 4oC on a mixer. After the bead bound cells (CD4+ 
T cells and CD14+ cells) were magnetically removed, the remaining cells, mostly CD8+ T 
cells, were resuspended in 1 ml of PBS with 3% FBS, gently agitated to release any 
trapped nonbound cells, and then magnetically reisolated. The purity of the CD8+ T cells 
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was confirmed by flow cytometry with a FACscaliber flow cytometer (Becton-
Dickinson, San Jose, CA) at the Veterinary Pathobiology Core Facility (Director, Dr. 
Roger Smith, Texas A&M University, College Station) (data not shown). 
 
Stimulation of effector cells by SFV-capsid expressing inducer cells 
FSF prepared from cat AZV2, were plated in 6 well plates (3 X 105 cells/well) 
and were transfected with SFV-capsid RNA, SFV lacZ RNA or SFV-1 RNA (vector 
only without any insert) using DMRIE-C (Gibco, BRL, Grand Island, N.Y.).  Five ug of 
RNA were used for each transfection reaction. Expression of SFV-capsid on the FSF 
was confirmed by an immunofluorescence assay (IFA), performed as described 
elsewhere (Brown et al.., 1991) (Fig. 1). Expression of lacZ was confirmed by adding X-
galactosidase (Promega, WI). These inducer cells transfected with SFV-capsid RNA, 
SFV-lacZ RNA or SFV RNA were overlaid 18 hours after transfection with autologous 
or heterologous effector cells (either fresh PBMC or CD8+ T cells) from FIV infected 
and uninfected cats. Every two days for six days, the non-adherent cells were harvested 
and centrifuged at 1200 rpm for 10 minutes (Jouan Inc., Winchester, VA), and the 
supernatants collected and stored at 4oC before overlaying the cells onto freshly prepared 
inducer cells.  Controls were non-transfected FSF cultured in the absence of effector 
cells, effector cells cultured without FSF and non-transfected FSF co-cultured with 
effector cells. The supernatants collected from these cells on days 2, 4 and 6 were stored 
at 4oC. 
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Fig. 1. Immunofluorescent staining of the FIV capsid protein expressed on FSF. Magnification 200X. 
 FIV capsid protein expressed on FSF after transfection of FSF with SFV vector expressing FIV capsid 
RNA (A). Untransfected FSF cells are shown in (B) (Since these cells are untransfected, the fluorescent 
antibody does not recognize any antigen, as a result of which the figure 1B appears blank). 
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Transwell separation of cells 
To assess the role of cell-cell contact in the induction of the effector cells, the 
irradiated inducer T cells were co-cultured with autologous effector PBMC in 6-well 
tissue culture plates in which the two cell populations were separated by a 0.45 um pore 
size polycarbonate membrane (Corning Incorporated, Acton, MA) at a ratio of 1:5 
inducer to effector cells in a total volume of 3 ml of complete RPMI. Inducer cells were 
also co-cultured with the effector PBMC, such that the inducer cells and the effector 
cells were in contact with each other. PBMC cultured without any inducer cells were 
used as controls. Newly irradiated inducer cells were added to the effector cells on the 
third day. The supernatants were collected on days 3 and 6 and stored at 4oC. 
 
Cross- reactivity of the CD8+ T cell antiviral activity from FIV-PPR infected cats 
In order to determine if the CD8+ T cell anti-viral activity from FIV-PPR infected 
cats was effective in suppressing replication of the Texas isolates, CD8+ T cells were 
enriched by negative selection from FIV infected cats, AZV2, AUO2, AUO3, AWF1, 
and E284. All CD8+ T cells with the exception of CD8+ T cells from cat AWF1 were 
stimulated by irradiated autologous FIV-PPR infected T cells for 6 days. On the third 
day, the supernatants were harvested from the co-culture and newly irradiated inducer T 
cells were added to the effector CD8+ T cells. The supernatants collected on days 3 and 6 
were stored at 4oC. As controls, the irradiated inducer cells were also cultured and 
supernatants were collected on days 3 and 6 and stored at 4oC. 
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FIV suppression assay 
Cell-free supernatants stored at 4oC were ultracentrifuged at 35,000 rpm for 2 
hours (Beckman L7-55 Ultracentrifuge, Palo Alto, CA) to remove the residual viral 
particles. The supernatants were passed through 0.22 um-pore size filters (Pall 
Corporation, Ann Arbor, MI) and stored at 4oC.  Target cells were prepared from PBMC 
of an FIV uninfected cat after culturing in vitro for six days with Con A and IL-2 (Choi 
et al., 2000b). They were then infected with the FIV-PPR strain and cultured with 
supernatants in a 96-well plate for 10 days at a medium to supernatant ratio of 1:1. 
Supernatant and fresh complete RPMI + hr IL-2 100 U/ml was added to the cells every 3 
days. The amount of FIV in the supernatants was determined by an FIV capsid antigen 
detection ELISA. Suppression was considered to be positive when virus expression was 
≤ 65% of virus expression in the untreated but FIV-PPR infected control cells (positive 
controls). 
To determine the cross reactivity of the CD8+ T cell antiviral activity, the FIV 
suppression assay was performed as mentioned above, with the exception that the target 
cells were infected with the TX078, TX53 or FIV-PPR strain.  
 
Data analysis 
 The differences in FIV replication between infected control cells and cells in 
which suppression of FIV was seen, were analyzed using Student’s t test (Ott, 1993). 
Statistically significant differences were set at p< 0.05. 
 
 34
RESULTS 
Kinetics of the induction process using either PBMC or CD8+ T lymphocytes as 
effector cells when FSF were used as inducer cells 
In order to determine the kinetics of the non-cytolytic activity following exposure 
to FSF inducer cells, supernatants were collected every 2 days from the co-culture of 
FSF from cat AZV2 and PBMC from either autologous or heterologous effector cells. 
The FSF were transfected with SFV vector expressing FIV capsid or an irrelevant 
antigen such as lacZ or the SFV vector expressing only its polymerase. In the presence 
of FSF, suppression was maximum on the 2nd and the 4th day but decreased by the 6th 
day as observed for FIV infected cats AZV2 (Fig. 2A) and AUO2 (Fig. 2B & 2C) and 
also for FIV uninfected cats OAE5 (Fig. 2D) and AUS3 (Fig. 2E). Thus, induction of the 
anti-FIV activity did not require autologous FSF as inducer cells.  
CD8+ T lymphocytes were enriched by negative selection, in order to ensure that 
the CD8+ T lymphocyte population within the PBMC contributed to the suppression of 
FIV replication in vitro. This population of CD8+ T lymphocytes contained not more 
than 5% macrophages and not more than 10% CD4+ T lymphocytes as determined by 
flow cytometry (data not shown). The kinetics of the soluble anti-FIV activity was 
determined using cat AZV2 FSF as inducer cells and enriched CD8+ T lymphocytes 
from FIV-infected cats, AZV2 (Fig. 3A) and AUO2 (Fig. 3B) and an FIV-uninfected cat 
AUS3 (Fig. 3C) as effector cells. Supernatants were collected every two days from the 
co-culture of autologous or heterologous CD8+ T lymphocytes and FSF transfected with 
SFV vector expressing FIV capsid or an irrelevant antigen such as lacZ or the SFV  
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A. 
 
 
Fig. 2. Kinetics of the induction process using fresh PBMC as effector cells when FSF were used as 
inducer cells. FSF prepared from cat AZV2 were transfected with Semliki Forest virus vector (SFV) 
expressing FIV capsid, an irrelevant antigen such as lacZ or SFV vector expressing only its polymerase, or 
left untransfected. Fresh PBMC from FIV-infected cats AZV2 (A), AUO2 (B and C) and FIV uninfected 
cats OAE5 (D) and AUS3 (E) were overlaid on FSF. Every 2 days the supernatants were collected and 
stored at 4oC and the non-adherent cells were overlaid on newly transfected FSF. As controls, supernatants 
were collected from untransfected FSF cultured without CD8+ T lymphocytes and PBMC cultured in the 
absence of FSF. The supernatants were ultracentrifuged and added to FIV-PPR infected target cells (cat 
OAE5 PBMC) every 3 days at a medium to supernatant ratio of 1:1. FIV production was determined by 
use of an FIV-capsid antigen detection ELISA. All the values have been normalized with respect to values 
obtained for untransfected FSF cultured without effector PBMC. 
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Fig. 2. Continued 
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Fig. 2. Continued 
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vector expressing only its polymerase. In contrast to studies using PBMC as a source of 
effector cells, when CD8+ T cells were used as effector cells, suppression of FIV 
replication was not only observed on day 6, but greater suppression was observed using 
supernatants collected on days 2 and 4 of induction of the effector CD8+ T cells for the 
three cats that were examined (Fig. 3A-3C). The presence of macrophages and/or CD4+ 
T cells may either dilute the suppression or actively inhibit the suppressive activity of 
CD8+ T effector cells.  
Interestingly, following induction with FSF transfected with SFV vector 
expressing an irrelevant antigen such as lacZ or SFV vector by itself, supernatants from 
effector CD8+ T cells or effector PBMC of infected cats, AZV2 and AUO2 and 
uninfected cats OAE5 and AUS3 were also able to suppress FIV replication in vitro (Fig. 
2A-2E, 3A- 3C). SFV vector without an insert expresses only the polymerase gene of the 
SFV virus during the course of transcription. It is possible that the polymerase or the 
viral RNA stimulates the effector cells, demonstrating that this kind of induction is not 
specific for FIV. Supernatants obtained from non-transfected FSF were not able to 
suppress FIV replication on any of the days examined (Fig. 2A-2E, 3A-3C). 
Supernatants from effector CD8+ T cells or effector PBMC cultured without FSF did not 
demonstrate any suppressing activity on any of the days examined (Fig. 2A, 2B and 2D, 
3A-3C). In addition, supernatants obtained from CD8+ T cells co-cultured with non-
transfected FSF did not show any suppressing activity (Fig. 3A-3C). Thus, non-
transfected FSF cells could not induce CD8+ T cells or PBMC to produce the anti-FIV 
activity.   
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Fig. 3. Kinetics of the induction process using CD8+ T lymphocytes as effector cells when FSF were used 
as inducer cells. FSF prepared from cat AZV2 were transfected with Semliki Forest virus vector (SFV) 
expressing FIV capsid, an irrelevant antigen such as lacZ or SFV vector expressing only its polymerase, or 
left untransfected. CD8+ T lymphocytes enriched from fresh PBMC from FIV-infected cats AZV2 (A), 
AUO2 (B) and FIV uninfected cat AUS3 (C) were overlaid on FSF. Every 2 days the supernatants were 
collected and stored at 4oC and the non-adherent cells were overlaid on newly transfected FSF. As 
controls, supernatants were collected from untransfected FSF cultured without CD8+ T lymphocytes, CD8+ 
T lymphocytes cultured in the absence of FSF and CD8+ T lymphocytes co-cultured with untransfected 
FSF. The supernatants were ultracentrifuged and added to FIV-PPR infected target cells (cat OAE5 
PBMC) every 3 days at a medium to supernatant ratio of 1:1. FIV production was determined by use of an 
FIV-capsid antigen detection ELISA. All the values have been normalized with respect to values obtained 
for untransfected FSF cultured without CD8+ T lymphocytes. 
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Fig. 3. Continued 
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Kinetics for the requirement of inducer cell-effector cell contact for the induction 
process 
Transwell cell culture plates were used to examine whether cell contact-mediated 
stimulation was necessary for the production of the soluble anti-FIV activity. When 
supernatants collected on day 7, from effector cells without direct contact with inducer 
cells were added to target cells, half suppressed virus replication (FIV infected cats 
AUO3, AWF1 and AZV2), however supernatants from the remaining FIV infected cats 
E238, E284 and OLQ5 did not (Phadke et al., 2004). Overall, the amount of suppression 
of FIV replication observed with the supernatants collected when the inducer and 
effector cells were in contact with each other was reduced by approximately 50% when 
the inducer and effector cells were separated in a transwell plate (Phadke et al., 2004). 
Therefore, inducer cell contact was required for optimal stimulation of effector cells for 
production of the soluble anti-FIV activity. 
The kinetics of the induction process using transwell culture plates indicated that 
the supernatants obtained from the co-culture of the autologous irradiated inducer T cells 
and the effector cells in contact with each other were able to suppress FIV replication on 
the third day (Fig. 4A) but this suppression was lost by the sixth day (Fig. 4B) for FIV 
infected cats AZV2, AUO2 and uninfected cat AUS3. However, when the inducer cells 
and the effector cells from FIV infected cats AZV2 and AUO2 were separated by a 0.45 
um membrane, the amount of suppression of virus replication seen on the third day was 
again reduced by nearly half of that seen when the inducer and the effector cells were in 
contact with each other. Effector cell supernatant from FIV uninfected cat AUS3 was 
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able to suppress FIV replication on either day 3 or day 6, but only marginally as 
compared with the infected cats. The supernatants from the PBMC cultured in the 
absence of inducer cells did not suppress FIV replication either on day 3 or day 6 for any 
of the cats examined (Fig. 4A & B). Thus, under the conditions where FSF were used as 
inducer cells or when FIV infected inducer T cells were separated from the effector cells, 
the optimal days for the induction of the soluble anti-FIV activity continued until the 
fourth day of induction, after which a decrease in the anti-FIV activity was consistently 
seen. 
 
The soluble anti-viral activity of CD8+ T cells from FIV-PPR infected cats is 
effective against individual FIV isolates from Texas 
 The supernatants from CD8+ T cells from five FIV-PPR infected cats suppressed 
replication of the FIV-PPR strain and two FIV isolates from Texas namely, TX53 and 
TX078 to different extents on days 3 and 6. Supernatants collected on day 3 from CD8+ 
T cells of cat AZV2 strongly suppressed replication of FIV-PPR (virus expression 1.4%) 
followed by FIV-TX078 (virus expression 9.4%) and FIV-TX53 (virus expression 
32.7%) (Fig. 5A). Supernatants collected on day 6 from CD8+ T cells of cat AZV2 were 
able to weakly suppress FIV-PPR (virus expression 51.7%) and FIV-TX078 replication 
(virus expression 59.7%), as determined by the 65% virus expression limit, but not FIV-
TX53 replication in the target cells (Fig. 5A) while. Supernatants collected either on day 
3 or day 6, from irradiated inducer T cells cultured without effector cells, did not 
suppress replication of any of the 3 viruses; FIV-PPR, FIV-TX53 and FIV-TX078. 
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Fig. 4.  Kinetics for the requirement of inducer cell-effector cell contact for the induction process. Fresh 
PBMC (effector cells) from FIV infected cats AZV2 and AUO2, and uninfected cat AUS3 were co-
cultured in contact with autologous irradiated FIV infected inducer T cells or separated from the inducer T 
cells by a 0.45 um membrane. Cell culture supernatants collected on days 3 (A) and 6 (B), were 
ultracentrifuged and added to FIV–PPR infected target cells (cat OAE5 PBMC) every 3 days at a medium 
to supernatant ratio of 1:1. FIV production was determined by use of an FIV capsid antigen detection 
ELISA. Values indicated by asterisks are significant (as calculated by the t test) among the three 
parameters examined, at 3 days for FIV-infected cats AZV2 and AUO2. 
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Fig. 5.  Cross- reactivity of soluble anti-viral activity mediated by CD8+ T cells. CD8+ T lymphocytes 
enriched from fresh PBMC from FIV-infected cats AZV2 (A), AUO2 (B), AUO3 (C), E284 (D) and 
AWF1 (E), were co-cultured with autologous irradiated inducer T cells for 6 days, with the exception of 
CD8+ T cells from cat AWF1. Irradiated inducer T cells were cultured as controls without effector cells. 
Cell culture supernatants collected on days 3 and 6, were ultracentrifuged and added to target cells (FIV 
uninfected cat AUS3 PBMC) every 3 days at a medium to supernatant ratio of 1:1. FIV production was 
determined by use of an FIV capsid antigen detection ELISA. The target cells were infected with FIV-
PPR, FIV-TX53 or FIV-TX078 strains.  
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Similar results were obtained for supernatants collected on day 3 from CD8+ T 
cells of cats AUO2 with observed virus expression of only 10.2%, 16.7%, and 27.7% for 
FIV-PPR, FIV-TX078 and FIV-TX53, respectively (Fig. 5B). In contrast to results for 
cat AZV2, the supernatants collected on day 6 from CD8+ T cells of cats AUO2 were 
able to strongly suppress replication of the three viruses in the target cells. Supernatants 
collected either on day 3 or day 6, from irradiated inducer T cells cultured without 
effector cells, did not suppress replication of any of the 3 viruses; FIV-PPR (data not 
shown), FIV-TX53 and FIV-TX078 (Fig. 5B). 
For cat AUO3, supernatants collected on day 3 from CD8+ T cells, showed 
stronger suppression of FIV-PPR replication (virus expression of 27.3%), as compared 
to FIV-TX078 (virus expression of 45.3%) with no suppression of FIV-TX53 replication 
(Fig. 5C). Suppression by supernatants collected on day 6 from CD8+ T cells was lost for 
all the three viruses examined. Once again, supernatants collected either on day 3 or day 
6, from irradiated inducer T cells cultured without effector cells, did not suppress 
replication of any of the 3 viruses; FIV-PPR (data not shown), FIV-TX53 and FIV-
TX078 (Fig. 5C). 
Supernatants collected on day 3 from CD8+ T cells of cat E284 showed a pattern 
of suppression similar to that seen for CD8+ T cells of cat AZV2. Thus, supernatants on 
day 3 strongly suppressed replication of FIV-PPR (virus expression 4.4%) followed by 
FIV-TX078 (virus expression 26.2%) and FIV-TX53 (virus expression 26.3%) (Fig. 
5D). Supernatants collected on day 6, however, suppressed the replication of only FIV-
PPR (virus expression 37.4%) but neither FIV-TX53 nor FIV-TX078 replication in the 
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target cells. Once again, supernatants collected either on day 3 or day 6, from irradiated 
inducer T cells cultured without effector cells, did not suppress replication of any of the 
3 viruses; FIV-PPR (data not shown), FIV-TX53 and FIV-TX078 (Fig. 5D). 
Finally, supernatants collected on day 3 from CD8+ T cells of cat AWF1 did not 
suppress replication of FIV-PPR strain and suppressed FIV-TX53 (virus expression 
62.2%) and FIV TX078 (virus expression 50.9%) replication very weakly as determined 
by the 65% virus expression limit (Fig. 5E). This slight suppression was also completely 
lost by day 6. Lack of strong suppression of virus replication of the three isolates by 
CD8+ T cell supernatant on day 3, from cat AWF1 was not surprising, since these CD8+ 
T cells were cultured without irradiated inducer T cells. This once again proved the 
necessary requirement of inducer cells for the induction of the CD8+ T cells to mediate 
the anti-FIV activity in our system. Overall, supernatants collected on day 3 from CD8+ 
T cells of cats AZV2, AUO2 and E284 demonstrated maximum suppression of the 3 
virus isolates examined.  
 
DISCUSSION 
These studies suggest that more than one pattern of induction stimulates antiviral 
activity in our chronically FIV infected and uninfected control cats. Studies performed in 
our laboratory consistently indicate that it is the CD8+ T cells within the population of 
PBMC that are responsible for the soluble anti-FIV activity (Choi et al., 2000b; Fig. 3A- 
3C). The various patterns of induction may stimulate several molecules that mediate 
CD8+ T cell suppressive activity against FIV. It is likely that the mechanism of induction 
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differs quantitatively and maybe even to a greater extent, qualitatively, leading to the 
induction of distinct antiviral factors. Moriuchi et al. (1996) have demonstrated that the 
HIV-suppressor activity of CD8+ T cell supernatants is multifactorial and that various 
factors within these supernatants including, but not limited to, the β-chemokines, may 
affect HIV replication at various stages of the life cycle of the virus. Due to the distinct 
CD8+ T cell suppressor activities that have been reported from various laboratories, 
Copeland (2002) has also suggested that the CAF activity in humans could represent 
more than one factor. Thus, it is possible that the various modes of induction, lead to the 
secretion of several molecules mediating the CD8+ T cell suppressive activity against 
FIV, and by inference, HIV. Suppression of FIV replication in our cats likely depends on 
the distinct patterns of induction resulting from the differences in the innate immune 
system of the cats, the course of infection and illness, and the differences in the genetics 
of the cats. The levels of suppressing activity generated have remained highly 
reproducible for each animal over several years, although variable from cat to cat. All 
the FIV infected cats in our colony have been infected between three to six years and are 
in the chronic asymptomatic stage of infection. The proviral load of these cats has been 
found to inversely correlate with their ability to suppress FIV replication in vitro 
(manuscript in preparation). It is possible that the suppressing activity of the CD8+ T 
cells actually helps to maintain the asymptomatic nature of the cats, because as yet, we 
have been unable to demonstrate anti-FIV CD8+ T cell suppressing activity in acutely 
infected cats.  
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The various types of cells that function in the induction of the effector cells and 
the communication required for the induction of the antiviral activity against FIV or HIV 
have not yet been defined. The focus of this study was to determine the requirements for 
induction of suppression of FIV replication, specifically whether T cells were necessary 
for induction of the feline CD8+ T cell suppressing activity and whether FIV infection 
was a criterion for cells to function as inducer cells. Inducer cells used in our initial 
studies were irradiated FIV-infected T lymphocytes (Choi et al., 2000b). But 
immortalized FSF, transfected with SFV vector expressing either the FIV capsid or an 
irrelevant antigen, such as lacZ or FSF transfected with SFV vector expressing only its 
polymerase, could also mediate the induction process. Either irradiated or non-irradiated 
FSF could serve as inducer cells (Phadke et al., 2004). The use of FSF transfected with 
SFV vector expressing the capsid protein of the FIV-PPR strain, might serve as a 
convenient alternative to the use of infected T cells as inducer cells in our system. Thus, 
it appears that functional inducer cells do not need to be professional antigen presenting 
cells (APC) and these cells do not have to express the viable and complete virus.  
The effector cells produced the soluble anti-FIV activity in the absence of MHC 
matched inducer cells when either FIV infected T cells or transfected FSF were used. 
This has been shown in our studies using autologous or heterologous inducer cells to 
stimulate the effector cells (Phadke et al., 2004). This is in contrast to the MHC class I 
restricted, FIV specific cytotoxic responses described for CD8+ T cells from our FIV 
infected cats, where autologous FIV-infected T cells were used as APC (Song et al., 
1992). In the studies with FSF, we have consistently shown that supernatants from 
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effector cells (either PBMC or CD8+ T cells) when co-cultured with mismatched FSF 
transfected with SFV vector expressing either the FIV capsid or an irrelevant antigen, 
such as lacZ or FSF transfected with SFV vector expressing only its polymerase, 
suppress FIV replication. In our studies, non-transfected FSF alone do not induce 
effector cells and although MHC restriction is not required for the soluble anti-FIV 
response, it is not yet clear as to whether it might improve or otherwise contribute to the 
activation of the effector cells. Our studies are in accordance with studies in HIV 
infection, where HLA compatibility at the effector phase was not required (Mackewicz 
et al., 1998). Thus, heterologous CD8+ T lymphocytes from one HIV infected individual 
were found to suppress HIV replication in naturally infected CD4+ T cells from another 
HIV-infected individual (Brinchmann et al., 1990).  
Optimal induction of the suppressing activity from the effector cells depended on 
cell-cell contact between inducer and effector cells, although approximately 50% of the 
suppressing activity could be demonstrated when the inducer and the effector cells were 
not in contact with each other. Therefore, membrane antigen interactions may be critical 
in the communication, while cytokines may play an accessory or a separate role in the 
induction process.  
CD8+ cytotoxic T cells from HIV-infected individuals have been shown to be 
specific for multiple epitopes within gag, env, nef, vif and pol gene products for HIV 
infected individuals and for env and gag gene products in FIV infected cats (Beatty et 
al., 1996; Flynn et al., 1994; Flynn et al., 1996; Gandhi and Walker, 2002; Li et al., 
1995; Song et al., 1992; Song et al., 1995). However, earlier studies of CD8+ T cell 
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mediated non-cytoxic antiviral activity against HIV have demonstrated lack of antigen-
specificity at the induction phase. Thus, in agreement with our studies, anti-HIV activity 
has been demonstrated from CD8+ T lymphocytes from HIV-uninfected, healthy 
individuals, CD8+ T cell clones derived from HIV-infected and uninfected individuals, 
cytotoxic T lymphocytes (CTLs) from HIV-1 uninfected individuals and even from cord 
blood (supposed to contain only naïve CD8+ T cells) from HIV-uninfected neonates 
(Bagasra and Pomerantz, 1993; Hsueh et al., 1994; Kootstra et al., 1997; Leith et al., 
1999; Liu et al., 2003; Mackewicz et al., 1997; Rosok et al., 1997; Song et al., 1992). 
Thus these studies demonstrated that induction of the anti-viral activity against HIV 
mediated by CD8+ T cells did not require prior exposure to HIV antigen and that it might 
not even necessarily require the presence of a virus for induction of CD8+ T cells.  
The CD8+ T cell mediated antiviral activity against HIV has also been found to 
demonstrate lack of antigen-specificity at the effector phase of control. Copeland et al. 
(1995) showed that CD8+ T cell supernatants from HIV-infected individuals (both 
primary and herpes-virus-samiri transformed CD8+ T cell lines) inhibited activation of 
LTRs of human T cell leukemia virus and Rous sarcoma virus in transiently transfected 
Jurkat cells. Walker et al. (1991b), demonstrated cross-reactivity, by showing that CD8+ 
T cells from an HIV-infected individual could suppress virus replication in CD4+ T cells 
acutely infected with HIV-1, HIV-2 or even SIVmac. CD8+ T cells from uninfected 
chimpanzees and chimpanzees infected with HIV-1SF2 could inhibit replication of HIV-
1SF33, explaining the natural resistance of chimpanzees to HIV- induced disease (Castro 
et al., 1991). In addition, CD8+ T cells of African green monkeys inhibited HIV-1 
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replication in human CD4+ T cells (Ennen et al., 1994) while CD8+ T cells of SIV-
infected sooty mangabeys inhibited the replication of HIV-2, SIV-1 (SIVsmm-7) and HIV-
1 (LAV) (Powell et al., 1990). Furthermore, CD3+CD8+ T cells of HIV-1 IIIB infected 
chimpanzees were shown to inhibit replication of HIV-1 strains IIIB, MN and RF in 
vitro (Husch et al., 1993). Moreover, this CD8+ T cell antiviral activity was shown to 
prevent superinfection of HIV-1 infected PBMC by diverse HIV isolates such as HIV-
1SF33, HIV-2UC2 and HIV-2UC3 (Locher et al., 1999). Prevention of superinfection due to 
soluble factor secreted by CD8+ T cells that suppressed virus replication was also 
observed in HIV-2 infected baboons that were challenged with either autologous or 
heterologous HIV-2 strains (Locher et al., 1997).  
Our results have also demonstrated that CD8+ T cell antiviral activity from FIV-
PPR infected cats suppressed replication of other retroviruses such as feline leukemia 
virus and HIV (Unpublished data from our laboratory). Hohdtasu et al., (2002) also 
demonstrated that the CD8+ T cell mediated anti-FIV activity was effective against FIV 
strains of subtypes that differed from the original FIV strain used to infect the target 
cells. They used FIV strains belonging to clades A, B and D in their studies, which 
therefore implies a role for CD8+ T cell antiviral activity in mediating resistance to 
superinfection in FIV infection. Moreover, the CD8+ T cell antiviral activity was found 
to be effective against heterologous FIV isolates such as FIV-Petaluma, FIV-GL8 and 
FIV-PPR belonging to the FIV clade A (Choi et al., 2000b; Flynn et al., 1999). In 
contrast to these studies, we have now demonstrated that CD8+ T cells from FIV-PPR 
cats were able to suppress viral replication in PBMC acutely infected with either FIV-
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TX53 or FIV-TX078 belonging to a newly emerging clade, which is closely related to 
clade B. Thus the soluble suppressing activity was interclade active in case of FIV, in 
agreement with the cross-reactivity and superinfection studies mentioned earlier. 
 The kinetics of the induction process demonstrated that antiviral activity against 
FIV was maximally expressed until day 4 after induction, but it was reduced appreciably 
or was absent by the 6th day when FSF were used as inducer cells (Fig. 2A-2E, 3A-3C). 
However, when CD8+ T cells of cat AUO2 were induced by irradiated inducer T cells 
and not FSF expressing FIV capsid, lacZ or transfected with SFV vector only, 
suppression of replication of FIV-PPR, FIV-TX53 and FIV-TX078 replication, was 
observed on day 6 also (Fig. 5B). This implies that interactions between the effector 
CD8+ T cells and the different inducer cells probably involve unique membrane 
interactions that generate various levels of FIV suppressing activity against different 
virus strains. Thus, understanding the mechanisms that activate and control suppression 
of FIV, may lead to our understanding of the natural process for controlling chronic 
lentiviral infection.   
FIV infected T cells and FSF transfected with SFV vector expressing the FIV 
capsid, an irrelevant antigen such as lacZ or FSF transfected with SFV vector only, 
could be used to induce the effector cells to suppress FIV replication in vitro. Both FSF 
and FIV-infected T cells would seem to require communication of some kind of crisis to 
induce the effector cells. Identifying alterations occurring with respect to membrane 
antigen expression within these two types of inducer cells will be valuable in 
understanding conditions needed for induction of effector cell synthesis of antiviral 
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activity. As the success of a FIV vaccine could be hampered by the occurrence of highly 
divergent viral variants in the field, the exploitation of this innate, soluble CD8+ T cell 
anti-FIV activity would be more useful. Hence, characterization and identification of the 
stimuli and mechanisms involved in the induction of the antiviral activity against FIV, 
not addressed in other studies, could provide information for strategies of practical 
exploitation of this innate T cell immunity and may contribute to the design of novel, 
safe and complementary anti-FIV therapeutic strategies. 
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CHAPTER III 
 
PHENOTYPIC CHANGES IN FRESH PERIPHERAL BLOOD 
MONONUCLEAR CELLS IN HEALTHY CATS AND CATS CHRONICALLY 
INFECTED WITH FELINE IMMUNODEFICIENCY VIRUS 
 
INTRODUCTION 
 A key step towards exploiting the soluble antiviral activity mediated by CD8+ T 
cells is to elucidate mechanisms that are responsible for stimulating the CD8+ T 
lymphocytes. The various types of cells that could function in the induction of the 
effector CD8+ T cells and the communication required for the induction of the antiviral 
activity against FIV or HIV have not as yet been defined. As described in chapter II, 
earlier studies in our laboratory have established that irradiated FIV-PPR infected T cells 
or immortalized feline skin fibroblasts (FSF) expressing either the FIV capsid, or an 
irrelevant antigen, such as lacZ or FSF transfected with SFV vector expressing only the 
polymerase, stimulate anti-FIV activity of CD8+ T cells (Choi et al., 2000b; Phadke et al., 
2004). These studies differ from studies in other laboratories (Bucci et al., 1998b; Flynn 
et al., 1999; Jeng et al., 1996) which relied on mitogen specific stimulation of CD8+ T 
cells to induce effector cells to generate anti-FIV activity.   
Production of the soluble anti-FIV activity from CD8+ T cells was shown in our 
studies using autologous or heterologous inducer cells to stimulate the effector cells. This 
is in contrast to the MHC class I restricted FIV specific cytotoxic responses described for 
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CD8+ T cells from our FIV infected cats where autologous FIV antigen expressing T 
cells were essential as inducer and target cells (Song et al., 1992). However, although 
MHC restriction is not required for the non-cytolytic anti-FIV response, it is not yet clear 
as to whether it might improve or contribute to the activation of the effector cells. 
 Optimal induction of the suppressing activity from the effector cells was shown 
to depend on cell-cell contact between inducer and effector cells, but lower levels of 
suppressing activity could be demonstrated when the inducer T cells and the effector 
cells were separated by a 0.45 um membrane in a transwell dish (Phadke et al., 2004). 
The requirement for cell contact indicates that cellular membrane antigen interactions are 
critical in the communication, while cytokines may play an accessory or separate role in 
the induction process. Cell-cell contact could depend on the interaction between 
costimulatory molecules and adhesion molecules, such as B7-1 (CD80), B7-2 (CD86), 
ICAM-1 or CD40, on the inducer cells with their respective ligands (CD28, CTLA-4, 
LFA-1 or CD40L) on the effector cells (Chirathaworn et al., 2002; Kochli et al., 1999; 
Kornbluth, 2002; Lenschow et al., 1996). It is likely that the separation of effector cells 
and inducer cells in the transwell prevented the various membrane antigen interactions, 
as a result of which the effector cells were not stimulated to generate supernatants that 
suppressed FIV replication in the target cells.  
Determining the phenotype of feline inducer T cells, with respect to expression of 
the various membrane antigens would enable us to identify various membrane antigens 
that might be involved in the induction process. In this study, fresh peripheral blood 
mononuclear cells (PBMC) from FIV infected and uninfected cats were analyzed for the 
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expression of various membrane antigens including CD4, CD8, MHC-I, MHC-II, Pan T 
marker and B7-1 molecules. Two-color flow cytometric analysis demonstrated a 
significant elevation of B7-1 on CD8+ T lymphocytes in FIV infected cats as compared 
to uninfected cats. 
 
MATERIALS AND METHODS 
Experimental animals and infection 
Specific, pathogen-free cats, purchased from Harlan Sprague-Dawley, Madison, 
WI or Liberty Laboratories, Liberty corner, N.J., were serologically negative for feline 
leukemia virus. Cats were housed in a specific, pathogen-free environment at the 
Laboratory Animal Research and Resources Support Facility (LARR), Texas A&M 
University, College Station. Cats AUO2, AUO3, AWF1, AZV2, A306, A308, E238, 
E284, M165, M242 and M153 were chronically infected with FIV PPR strain. These cats 
had been inoculated with 50 to 1250 TCID50 of virus i.v. three to six years prior to these 
studies. All the cats were in the asymptomatic stage of infection. Cats AUS3, OAE5, and 
OLQ4, sham inoculated with saline solution were used as uninfected control cats. 
 
Antibodies  
Fluorescein isothiocyanate (FITC) conjugated monoclonal antibodies (Mab) to 
feline CD4, feline CD8 (CD8β chain) (Southern Biotechnology Associates, Birmingham, 
AL) and unlabeled Mabs to feline MHC class I and MHC class II molecules (VMRD, 
Inc., Pullman, WA) were purchased commercially. Anti-feline B7-1 Mab (clone 
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B7.1.66) and a Mab that recognizes feline T cells (clone 1.572) were kindly provided by 
Dr. Wayne Tompkins (North Carolina State University, Raleigh, NC). Rabbit polyclonal 
antibodies to feline B7-1 and B7-2 were provided by Barbara Winslow (Schering-Plough 
Animal Health, San Diego, CA). Rabbit polyclonal antibody to feline CTLA-4 was 
developed in our laboratory (Choi et al., 2000a). The specificities of the rabbit polyclonal 
antibodies to feline B7-1, B7-2 and CTLA-4 respectively, have been confirmed 
(Tompkins et al., 2002). Secondary antibodies, including phycoerythrin (PE) conjugated 
goat anti-mouse (GAM) IgG1, FITC conjugated GAM IgG2a and PE conjugated GAM 
IgG2a, were purchased from Southern Biotechnology Associates (Birmingham, AL). 
 
Staining of freshly prepared PBMC 
 Lymphocyte subsets were determined in peripheral blood collected by jugular 
venipuncture into EDTA (K3)-containing tubes. Feline PBMC were isolated from EDTA 
(K3)-treated whole blood by Histopaque-1077 (Sigma, St. Louis, MO) density gradient 
centrifugation (Choi et al., 2000b) and washed once with cold phosphate-buffered saline 
(PBS) containing 0.1% sodium azide. Prior to staining of the cells, the Fc receptors on 
the cells were blocked by incubating the cells for 10 minutes on ice with goat anti-IgG (2 
mg/ml) (Sigma, St. Louis, MO). Two-color flow cytometric analysis was performed with 
freshly isolated PBMC to determine the expression of B7-1 on CD4+ T cells, CD8+ T 
cells, or on total T cells (using a feline pan T antibody), MHC class I on CD4+ or CD8+ T 
cells and MHC class II on CD4+ or CD8+ T cells. FITC conjugated Mabs to feline CD4 
and feline CD8 and unlabeled Mab to feline MHC class I and feline MHC class II in cold 
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PBS-0.1% sodium azide were added to the cells in the respective tubes at a final dilution 
of 1:50. The anti-feline B7-1 Mab and anti-feline pan T Mab were used undiluted in 50 
ul volume. After incubating for 30 minutes on ice, the cells were washed once with cold 
PBS-0.1% sodium azide and centrifuged at 1200 rpm for 10 minutes (Jouan Inc., 
Winchester, VA). PE conjugated GAM IgG1 (Southern Biotechnology Associates, 
Birmingham, AL) in cold PBS-0.1% sodium azide was added at a dilution of 1:250 to 
tubes containing cells stained for B7-1 and MHC class I molecules. FITC-conjugated 
GAM IgG2a and PE conjugated GAM IgG2a (Southern Biotechnology Associates, 
Birmingham, AL) in cold PBS-0.1% sodium azide were added to tubes containing cells 
stained for Pan T marker and MHC class II molecules, respectively, at a dilution of 1:50. 
After incubating for 30 minutes on ice, the cells were washed once with cold PBS-0.1% 
sodium azide and centrifuged at 1200 rpm for 10 minutes. Negative controls consisted of 
isotype-matched controls and unstained cells. After washing the cells, 300 ul of 2% 
formaldehyde were added to the tubes, which were wrapped in an aluminium foil and 
kept at 4oC until they were examined the following day with a FACscaliber flow 
cytometer (Becton-Dickinson, San Jose, CA) at the Veterinary Pathobiology Core 
Facility (Director, Dr. Roger Smith, Texas A&M University, College Station). 
 
Cell culture 
  Feline PBMC were isolated from EDTA (K3)-treated whole blood by Histopaque-
1077 (Sigma, St. Louis, MO) density gradient centrifugation (Choi et al., 2000b). PBMC 
were cultured as described previously with RPMI 1640 (Gibco BRL, Grand Island, 
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N.Y.), supplemented with 10% heat inactivated fetal bovine serum (FBS) (Atlas 
Biologicals, Fort Collins, CO), 50 ug/ml of gentamicin (Gibco BRL, Grand Island, 
N.Y.), 5 x 10-5 M 2-mercaptoethanol (Gibco BRL, Grand Island, N.Y.), 2mM L-
glutamine (Gibco BRL, Grand Island, N.Y.), and 100 U of human recombinant IL-2 (hr 
IL-2) (Gibco BRL, Grand Island, N.Y.) per ml (Choi et al., 2000b). Cells were grown at 
37oC in a humidified atmosphere of 5% CO2. 
 
Preparation of FIV-PPR infected inducer T cells   
Feline T cells were infected with FIV-PPR strain and irradiated (11,000 rads from 
a 6oCo source provided by the Nuclear Science Center, Texas Engineering Experiment 
Station, College Station) before using as inducer cells for stimulation of effector cells, as 
previously described (Choi et al., 2000b; Song et al., 1992). Briefly, freshly prepared 
PBMC were stimulated for three days with 5 ug/ml of Concavalin A (Con A) (Sigma, St. 
Louis, MO). The stimulated cells were centrifuged at 1200 rpm for 10 minutes (Jouan 
Inc., Winchester, VA) and infected with FIV-PPR for 1 h at 37oC. The cells were washed 
before culturing in complete RPMI containing 100 U hr IL-2 per ml. After 6 days of 
incubation, virus replication was monitored using the FIV capsid antigen ELISA. These 
FIV-infected cells were cryo-preserved to be used later as inducer cells. 
 
Blocking studies 
In order to determine the role, if any, of the B7 molecules in the induction 
process, irradiated autologous inducer T cells were incubated with the following 
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antibodies for 1 hour in a humidified atmosphere of 5% CO2; Mab to feline B7-1,  rabbit 
polyclonal antibody to feline B7-1, rabbit polyclonal antibody to feline B7-2, rabbit 
polyclonal antibody to feline CTLA-4, a combination of Mab to feline B7-1 and  rabbit 
polyclonal antibody to feline B7-2 and a combination of rabbit polyclonal antibodies to 
feline B7-1 and feline B7-2. Negative controls consisted of irrelevant hybridoma 
supernatant and pre-immune rabbit serum. After 1 hour, effector cells (fresh PBMC) 
from FIV infected cats AU02, A306, M165 and FIV uninfected cat OLQ4 were added to 
the inducer cells at a ratio of 1 inducer for 10 effector cells. On the 3rd day, the cells were 
harvested and centrifuged at 1200 rpm for 10 minutes (Jouan Inc., Winchester, VA), and 
the supernatants were collected and stored at 4oC.  
 
FIV suppression assay 
Cell-free supernatants stored at 4oC were ultracentrifuged at 35,000 rpm for 2 
hours (Beckman L7-55 Ultracentrifuge, Palo Alto, CA) to remove the residual viral 
particles. The supernatants were passed through 0.22 um-pore size filters (Pall 
Corporation, Ann Arbor, MI) and stored at 4oC. Target cells were prepared from PBMC 
of an FIV uninfected cat after culturing in vitro for six days with Con A and IL-2 (Choi 
et al., 2000b). They were then infected with the FIV-PPR strain and cultured with 
supernatants in a 96-well plate for 10 days at a medium to supernatant ratio of 1:1. 
Supernatant and fresh complete RPMI + hr IL-2 100 U/ml were added to the cells every 
3 days. The amount of FIV in the supernatants was determined by an FIV capsid antigen 
detection ELISA. Suppression was considered to be positive when virus expression was 
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≤ 65% of virus expression in the untreated but FIV-PPR infected control cells (positive 
controls). 
 
Data analysis 
 The differences in the percentages of cells between FIV infected and uninfected 
cats were analyzed using Student’s t test (Ott, 1993). Statistically significant differences 
were set at p < 0.05. 
 
RESULTS 
Expression of various membrane molecules on freshly prepared PBMC from FIV 
uninfected cats and cats chronically infected with FIV-PPR strain 
In order to determine the phenotype of inducer T cells used in our studies, fresh 
PBMC from 11 chronically FIV infected cats and from 3 uninfected cats were analyzed 
for surface expression of CD4, CD8, B7-1 expression on T cells, B7-1 expression on 
CD4+ T cells or CD8+ T cells, MHC class I expression on CD4+ T cells or CD8+ T cells 
and MHC class II expression on CD4+ T cells or CD8+ T cells. Analysis of the data 
indicated that there was no significant difference in the CD4+/CD8+ T cell ratio between 
FIV infected and uninfected cats (Table 1). In addition, there was no significant 
difference in the percentages of double-labeled CD4+ and CD8+ T cells from FIV 
infected and uninfected cats expressing either MHC class I or MHC class II molecules 
(Table 1). Analysis of two-color flow cytometry of fresh PBMC demonstrated that the 
percentage of B7-1+ peripheral blood CD8+ T cells from FIV-infected cats was 
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significantly greater (p < 0.05) as compared to uninfected cats (Figs. 6, 7). However, the 
percentage of B7-1+ peripheral blood CD4+ T cells and the percentage of peripheral total 
B7-1+ T cells was not significantly different between FIV-infected and uninfected cats 
(Figs. 6, 7 and Table 1).   
 
Effect of blocking costimulatory interactions mediated by B7-1 and B7-2 on the 
ability of the effector cells to suppress FIV replication in vitro 
Flow cytometry studies indicated a greater percentage of B7-1+ peripheral blood 
CD8+ T cells in FIV infected cats as compared to FIV uninfected cats (Fig. 6). 
Costimulatory molecules B7-1, B7-2 and CTLA-4 were shown to be up regulated by 
stimulation of feline CD4+ and CD8+ T cells with concavalin A (ConA) or the 
combination of phorbol myristate acetate (PMA) and ionomycin (I) (Vahlenkamp et al., 
2004). Based on these observations, attempts were made to block the B7 interactions in 
order to determine which of the B7 molecules might be involved in the ability of inducer 
T cells to increase the CD8+ T cell antiviral activity. If the costimulatory molecules were 
important in the induction process, the supernatants derived from blocking B7-1 and B7-
2 interactions between inducer and effector cells would not suppress FIV replication. 
However inconclusive results were obtained for the 4 cats studied, 3 FIV infected cats, 
M165, AUO2 and A306 and one uninfected cat OLQ4 (data not shown), because the 
supernatants derived from inducer and effector cells co-cultured with pre-immune rabbit 
serum (control for polyclonal antibody) suppressed FIV replication to the same extent as 
the supernatants generated in the presence of feline specific polyclonal antibodies, 
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Table 1 
Analysis of phenotypes of fresh PBMC from uninfected cats and cats chronically 
infected with the FIV-PPR strain 
Cats FIV-PPR virus dose 
% of Single-
labeled cells 
  
% of Double-labeled cells 
  T cells 
      % MHC-I + % MHC-II+ 
    
 
CD4+ 
 
CD8+ 
CD4/ 
CD8 
ratio 
 B7-
1+  
 
CD4+ 
  
CD8+  
 
CD4+  
 
CD8+ 
          
OAE5 Uninfected 21.10 14.10 1.50 27.70 100.0 100.0 92.10 83.30
OLQ4 Uninfected 25.00 10.20 2.45 39.50 100.0 100.0 7.30 54.50
AUS3 Uninfected 14.20 10.50 1.35 32.80 100.0 100.0 96.80 98.70
          
AZV2 50 12.10 8.70 1.39 54.50 100.0 100.0 82.30 91.00
AUO2 50 11.70 14.30 0.82 39.20 99.9 99.8 85.30 83.50
AUO3 50 18.70 17.40 1.07 57.10 99.9 99.8 99.80 99.20
AWF1 50 16.80 8.40 2.00 49.60 99.7 100.0 85.80 91.80
E238 1250 18.20 12.60 1.44 35.80 100.0 99.9 95.50 88.40
E284 1250 29.00 19.80 1.46 33.40 100.0 99.9 83.10 85.60
A306 250 24.80 9.10 2.73 64.20 100.0 100.0 92.10 91.70
A308 250 20.80 14.10 1.48 72.40 100.0 100.0 97.60 97.50
M242 50 39.40 24.30 1.62 16.10 99.9 100.0 45.40 61.20
M153 50 19.10 33.70 0.57 33.60 100.0 99.8 11.50 22.80
M165 50 21.20 21.20 1.00 43.30 100.0 100.0 36.40 38.90
 
Fresh PBMC from 3 FIV-uninfected cats and 11 chronically FIV infected cats were singly or doubly 
stained for the expression of various membrane molecules as explained in the materials and methods. 
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Fig. 6.   Percentage of B7-1+ CD4+ and B7-1+ CD8+ T cells from freshly prepared PBMC of FIV infected 
and uninfected cats. Fresh PBMC from 11 FIV infected cats and 3 uninfected cats were evaluated for the 
expression of B7-1 on their CD4+ and CD8+ T cells by double labeling the cells as explained in the 
materials and methods.  
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Fig. 7.  Comparison of percentages of B7-1+ CD4+ T cells and B7-1+ CD8+ T cells from freshly prepared 
PBMC of FIV infected and uninfected cats. Freshly prepared PBMC from 11 FIV infected cats and 3 
uninfected cats were double labeled as explained in the materials and methods and evaluated for the 
expression of B7-1 on their CD4+ and CD8+ T cells. The percentage of B7-1+ peripheral blood CD8+ T 
cells from FIV-infected cats was significantly greater (p < 0.05) as compared to uninfected cats as 
indicated by asterisks.  
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indicating that blocking was not specific with the rabbit serum. Moreover, addition of the 
irrelevant hybridoma supernatant to the co-culture of effector cells and inducer cells 
generated supernatants that were able to suppress FIV replication. This once again 
indicated that virus suppression observed was the result of non-specific inhibition from 
polyclonal or monoclonal antibodies to feline antigens. 
 
DISCUSSION 
Recently, a number of studies have attempted to elucidate the phenotype of the 
CD8+ T cells responsible for mediating the suppression of either FIV or HIV (Bucci et 
al., 1998b; Gebhard et al., 1999; Landay et al., 1993; Toso et al., 1995; Zanussi et al., 
1996). In cats, the CD8+ T effector cells responsible for suppression of the virus bear an 
activation phenotype characterized by low levels of CD8β chain (CD8α+βlow) and L-
selectin (CD62L), as well as high levels of CD44, CD49d and CD18 (Bucci et al., 1998b; 
Gebhard et al., 1999). Most of these studies have used mitogen stimulated CD8+ T 
lymphocytes for generation of anti-FIV activity. However, studies carried out in our 
laboratory have consistently shown that CD8+ T lymphocytes required stimulation by 
inducer cells (either T cells or FSF), and not mitogen for the generation of maximum 
anti-FIV activity (Choi et al., 2000b; Phadke et al., 2004). Hence, characterizing the 
phenotype of inducer T cells is essential for understanding the mechanisms required for 
stimulation of CD8+ T lymphocytes. 
Towards this end, fresh PBMC from 11 chronically FIV infected cats and three 
FIV uninfected cats were analyzed for surface expression of various membrane antigens. 
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There was no significant difference between the MHC class I and MHC class II 
expression on CD4+ T cells or CD8β+ T cells either from FIV infected or uninfected cats. 
This is inconsistent with other reports describing increased expression of MHC class II 
on CD8α+βlow T cells in FIV-infected cats (Ohno et al., 1992; Rideout et al., 1992; 
Willett et al., 1993). Willett et al. (1993) observed an MHC class II increase in 
CD8α+βlow PBMC of cats that were intraperitoneally infected with FIV-A-GL8 strain 
between 2-18 months prior to analysis. Rideout et al. (1992) observed MHC class II 
upregulation on CD8+ T cells from cats intravenously infected with FIV-A-Petaluma for 
3 months or 5 years. In contrast, Shimojima et al. (2003) found that activated CD8+ PBLs 
from cats that been infected vaginally by FIV-B-TM2 strain had downregulated MHC 
class II expression as compared to unprimed lymphocytes, which was also demonstrated 
by Reubel et al. (1994) on PBMC from experimentally FIV infected cats. However it is 
thought that expression of MHC class II molecules is not a reliable marker for feline T 
cell activation as it is for human T cells, because of low-level constitutive expression in 
naïve T cells (Rideout et al., 1990). 
Surprisingly, the percentage of B7-1+ peripheral CD8+ T cells from FIV 
chronically infected cats was significantly greater as compared to the percentage of B7-
1+ CD8+ T cells from FIV uninfected cats. There was no significant difference in the 
percentages of peripheral B7-1+ CD4+ T cells betwen FIV infected and uninfected cats 
(Fig. 6, 7). Expression of the B7-1 costimulatory molecule on T cells is unusual since 
these molecules under normal physiologic conditions are found on professional antigen 
presenting cells (APC), such as dendritic cells, B cells and macrophages (Lenschow et 
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al., 1996). However, a number of recent studies have shown that B7 molecules may be 
up regulated on T cells activated in vitro and on a subset of CD4+ and CD8+ T cells in 
HIV or FIV infection (Haffar et al., 1993; Kochli et al., 1999; Tompkins et al., 2002; 
Wyss-Coray et al., 1993b).  Studies carried out by Tompkins et al. (2002), using cats 
infected with the North Carolina FIV isolate (NCSU) have indicated that although B7-1+ 
CD4+ and B7-1+ CD8+ T cells were present in both blood and lymph nodes of FIV-
infected cats, B7-2+ T cells were for the most part restricted to lymph nodes.  Wolthers et 
al. (1996) reported that B7-2 and not B7-1 expression on freshly isolated CD3+ T cells 
was significantly higher among HIV infected individuals as compared to HIV uninfected 
individuals. They also reported increased B7-1 and B7-2 expression on CD4+ and CD8+ 
T cells from HIV infected persons as compared to control subjects, after stimulation of 
these cells with either mitogen (PMA/I) or a combination of CD2 and CD28 antibodies 
(Wolthers et al., 1996). Kochli et al., (1999) demonstrated that B7-2 expression and not 
B7-1 expression on fresh peripheral blood CD4+ and CD8+ T cells among HIV infected 
individuals was significantly higher as compared to HIV uninfected individuals. 
According to studies by Wyss-Coray et al. (1993b), examination of a limited number of 
HIV-infected patients (n = 12) revealed that 0.5% - 20% of CD3+ T cells in fresh PBMC 
expressed B7 molecules, whereas none of the CD3+ T cells from PBMC of healthy 
patients (n = 5) expressed B7. Additionally, Jason et al. (1999) demonstrated a relatively 
higher proportion of HIV-capsid (p24)+ CD3+ T lymphocytes expressing B7-1 and B7-2 
than p24- CD3+ lymphocytes. In our studies, we have been unable to determine 
percentages of feline B7-2 for lack of a monoclonal antibody to feline B7-2. However, 
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increased percentage of peripheral B7-1+ CD8+ T cells was observed in our FIV infected 
cats as compared to FIV uninfected cats. 
On the other hand, it is likely that the expression of costimulatory molecules is a 
reflection of the chronicity of T cell activation during HIV infection (Kochli et al., 1999) 
since the percentage  of actively HIV infected CD4+ T cells is < 0.02%  which is far less 
than the percentage of T cells with an APC phenotype. Human T lymphotropic virus 
(HTLV- also a retrovirus) infected T lymphocytes constitutively express B7-1 and B7-2 
concomitant to the down-modulation of CD28 on T cells. In HTLV infection, such B7-
1+/ B7-2+ T cells serve as APC, leading to a sustained proliferation of T cells, and both 
the ligands have been found to participate in allostimulation, autologous proliferation as 
well as spontaneous proliferation of HTLV-II infected PBMC (Lal et al., 1996).  
Activated or in vitro stimulated T cells also express B7-1 and B7-2 molecules in 
addition to MHC-II molecules (HLA-DR), suggesting that those T cells might function 
as APC (Azuma et al., 1993; Pichler and Wyss-Coray, 1994; Wyss-Coray et al., 1993a).  
Studies with HIV infected individuals have shown that, during infection, T cells 
themselves develop an antigen presenting phenotype by upregulating expression of 
HLA-DR, B7-1 and B7-2 molecules. The more the disease progresses, the less CD28 and 
more DR and B7-2 are found on circulating T cells (Kochli et al., 1999). Activated T 
cells from HIV infected individuals have also been found to present the HIV envelope 
protein gp120 (Lanzavecchia et al., 1988; Siliciano et al., 1988). Based on these 
observations and the flow cytomtery results discussed, it is possible that similar to HIV 
infection in humans, T cells from FIV infected cats develop an antigen presenting 
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phenotype and hence contribute to the stimulation of effector CD8+ T cells as described 
earlier (Choi et al., 2000b; Phadke et al., 2004). 
The B7 family of proteins, B7-1 and B7-2, provide the major costimulatory signal 
for augmenting and sustaining T-cell response via interaction with the CD28 
costimulatory receptor. Binding to another receptor on activated T cells, CTLA-4 leads 
to antigen specific anergy in mice (Lenschow et al., 1996; McAdam et al., 1998). In the 
case of HIV infection, CD8+ T cell antiviral factor production has been found to be 
associated with cells expressing CD8, CD38, HLA-DR and CD28 antigens (Jiang et al., 
2003). Engagement of the CD28 molecule on CD8+ T cells from AIDS patients during 
stimulation in vitro was found to restore and enhance the ability of these cells to suppress 
HIV replication (Barker et al., 1997). Moreover, blocking the interaction of CD28 and 
B7 molecules with a CTLA-4Ig fusion protein abrogated the ability of autologous 
macrophages to enhance this CD8+ T cell antiviral activity (Barker et al., 1997). Barker 
et al. (1999) demonstrated that while both B7 molecules could deliver a costimulatory 
signal sufficient to increase CD8+ T cell antiviral activity, B7-2 was found to be the 
molecule on macrophages that enhanced CD8+ T cell suppression of HIV replication.  
Hence in order to determine the role played by B7 molecules in the induction of anti-FIV 
activity in our system, interactions of B7 with their receptors were blocked using anti-
feline B7-1 antibody, anti-feline B7-2 antibody or anti-feline CTLA-4 antibody. 
However, the results obtained using antibodies to feline B7-1, B7-2 and CTLA-4 were 
not conclusive as the antibody controls (pre-immune rabbit serum and the irrelevant 
hybridoma supernatant) demonstrated non-specific suppression, making it difficult to 
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determine the role of B7-1 and B7-2 molecules expressed on inducer T cells in the 
induction of CD8+ T cells to mediate the anti-viral activity.   
 In conclusion, the percentage of B7-1+ peripheral CD8+ T cells from FIV 
chronically infected cats was significantly greater as compared to the percentage of B7-
1+ CD8+ T cells from FIV uninfected cats, but its relevance to the induction of 
suppressing activity against FIV is presently unknown. 
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CHAPTER IV 
 
PATHOGENENSIS OF A TEXAS FIV ISOLATE WHICH BELONGS TO AN 
EMERGING SUBTYPE CLOSELY RELATED TO FIV CLADE B  
 
INTRODUCTION 
 Feline immunodeficiency virus (FIV), a lentivirus, within the family 
Retroviridae, causes an AIDS-like disease in naturally and experimentally infected cats, 
similar to that seen in human immunodeficiency virus (HIV) infection of humans. FIV 
resembles HIV in terms of its morphology, genome organization and Mg2+ dependency 
of its reverse transcriptase (Olmsted et al., 1989b; Pedersen et al., 1987; Talbott et al., 
1989; Yamamoto et al., 1989). After primary infection, the clinical course of FIV 
infection in cats also parallels that seen in HIV infection in humans. Cats develop an 
acute infection illness similar to that seen in HIV infection including low grade fever, 
transient lymphadenopathy and transient leucopenia due to an absolute neutropenia 
(Barlough et al., 1991; Callanan et al., 1992; Yamamoto et al., 1988). In vivo, FIV 
causes an early plasma and cell-associated viremia, followed by a strong antibody 
response that correlates with reduction in plasma viremia (Diehl et al., 1995a; 
Yamamoto et al., 1988). This is followed by a long asymptomatic period of varying 
duration characterized by inverted CD4+/ CD8+ T cell ratios due to a decrease in CD4+ T 
cells and sometimes due to a corresponding increase in the CD8+ T cells (Ackley et al., 
1990; Tompkins et al., 1991; Torten et al., 1991).  The increase in CD8+ T cells has been 
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reported to include a population of CD8+ T cells expressing low levels of CD8 (CD8low) 
and increased levels of MHC class II antigens (Willett et al., 1993). Furthermore, the 
onset of immunodeficiency is also marked by a reduced responsiveness of feline 
peripheral blood mononuclear cells (PBMC) to in vitro mitogenic stimulation (Siebelink 
et al., 1990; Torten et al., 1991). The asymptomatic period progresses to a stage 
characterized by a variety of AIDS-associated disorders, such as opportunistic 
infections, chronic gingivitis or stomatitis, chronic upper respiratory infections, 
superficial and systemic fungal infections, ocular disease and chronic enteritis 
(Bendinelli et al., 1995; Pedersen, 1992). As with human AIDS patients, FIV infected 
cats usually die from a chronic wasting syndrome, neurologic disease, neoplasia or 
systemic opportunistic infections (Bendinelli et al., 1995; Hutson et al., 1991; 
Yamamoto et al., 1989). Similarities in biological characteristics and disease progression 
to AIDS have made FIV a relevant small animal model for studying lentiviral 
pathogenesis and therapeutic strategies. 
 FIV isolates can be subdivided into five distinct phylogenetic clades, designated 
A to E based on the nucleotide sequences from the envelope gene (Bachmann et al., 
1997; Elder et al., 1998; Sodora et al., 1994). Those numbers can be expected to increase 
as further studies reveal additional diversity. Clade B viruses are significantly diverse 
with three phylogenetically and evolutionary distinguishable groups (Bachmann et al., 
1997). In fact, recent studies from our laboratory have indicated the evolution of an 
emerging subtype of FIV isolates in Texas that appear to have shared a common 
ancestor with clade B isolates (Weaver et al., 2004). Studies by Sodora et al. (1994) have 
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suggested that FIV subtype B was in a more advanced state of adaptation to the host, and 
may be less pathogenic than subtype A. In their study, none of the cats from which 
subtype B viruses were obtained had evidence of disease, although some of them had 
low CD4+ T cell numbers.  Three viral isolates, namely FIV subtype B strain 2542, FIV-
TM1 and FIV-TM2 belonging to clade B, have been studied for pathogenicity with 
contrasting results (Burkhard et al., 2001; Diehl et al., 1995a; Diehl et al., 1995b; 
Kohmoto et al., 1998; Yamamoto et al., 1997). Although the three isolates caused 
immunodeficiency with an inversion of CD4+/ CD8+ T cell ratios, FIV clade B strain 
2542 was shown to cause fatal immunodeficiency in cats (Elder et al., 1998). 
 The major obstacle for acceptance of FIV as a small animal model for human 
AIDS has been the long and protracted disease course associated with infection with 
most FIV strains. Under experimental conditions 3 FIV isolates have shown to 
consistently induce fatal immunodeficiency disease: A molecularly cloned clade A FIV 
NCSU1 virus (English et al., 1994; Yang et al., 1996) and rapidly passaged clade B and 
clade C FIV isolates (Bachmann et al., 1997; Diehl et al., 1995b; Elder et al., 1998). 
FIV-C-PGammer rapidly killed two-thirds or more of the kittens infected intravenously 
(i.v.) at less than 12 weeks of age (Diehl et al., 1996; Diehl et al., 1995b). However, the 
virulence appeared to be age-restricted because cats 8-12 months of age were unable to 
demonstrate this rapid disease course seen with kittens (Pedersen et al., 2001). 
 The Texas (TX) isolates were isolated from naturally infected feral cats which 
were either asymptomatic or showed varying clinical abnormalities, such as skin lesions, 
and lymphoid hyperplasia in addition to the presence of tapeworms and roundworms at 
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necropsy. These TX isolates formed a distinct cluster when compared with FIV strains 
from other known clades (Weaver et al., 2004). Disease caused by experimental 
infection of cats with the TX isolates has not yet been demonstrated. The following 
study was undertaken with the goal to determine if the TX isolates, specifically FIV-
TX53 differed from other known FIV strains in its ability to cause disease in the acute 
stage of experimental infection.  
 
MATERIALS AND METHODS 
Animals and virus inoculations 
Twelve specific, pathogen-free (SPF), 4 month old male kittens were purchased 
from Harlan Sprague Dawley (Indianapolis, IN). They were housed in a specific, 
pathogen-free environment, for the duration of the experiments at Laboratory Animal 
Research and Resource support facilities (LARR), Texas A&M University, College 
Station. 
 The kittens were randomly divided into four groups of 3 individuals 1 week 
before inoculation to re-establish dominance hierarchies. The negative control group was 
sham inoculated i.v. with 1 ml of sterile phosphate buffered saline (PBS) only. The three 
treatment groups received 1 ml of sterile PBS containing the FIV-TX53 strain of FIV at 
titers of 500, 2000 or 8000 TCID50. Following inoculation, general health was monitored 
daily for 15 days post infection (p.i.) and then every two days until 9 weeks p.i. 
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Preparation of feline peripheral blood mononuclear cells (PBMC) 
Whole blood was drawn by jugular venipuncture 1 week prior to infection and at 
2, 4, 7, 9 and 11 weeks p.i. Feline PBMC were isolated from EDTA (K3)-treated whole 
blood by Histopaque-1077 (Sigma, St. Louis, MO) density gradient centrifugation (Choi 
et al., 2000b). Unstimulated fresh PBMC, collected 1 week prior to infection and during 
weeks 2, 4, 7, 9 and 11 p.i. were used to determine CD4+/CD8+ T cell ratios, for proviral 
DNA PCR and complete blood counts.  
 
Virus 
FIV-TX53 (AY139109) was propagated in PBMC from the feral cat from which 
it was isolated. After 7 to 10 days of infection, virus replication was evaluated with an 
FIV capsid antigen detection enzyme-linked immunosorbent assay (ELISA) (Choi et al., 
2000b). Supernatants with an optical density (OD) of more than 2 were collected and 
these stocks were stored at –80o C. The FIV-TX53 virus stock had a titer of 0.5 x 106 / ml 
TCID50, determined as described earlier (Hokanson et al., 2000). 
 
Complete blood counts and CD4+/CD8+ T cell staining of freshly prepared PBMC 
Complete blood counts were determined by the Texas Veterinary Medical 
Diagnostic laboratory (TVMDL) at Texas A&M University in order to monitor 
lymphocyte and neutrophil levels. PBMC from 9 FIV infected and 3 uninfected cats were 
isolated from EDTA (K3)-treated whole blood by Histopaque-1077 (Sigma, St. Louis, 
MO) density gradient centrifugation (Choi et al., 2000b) and washed once with cold 
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phosphate-buffered saline (PBS) containing 0.1% sodium azide. Prior to staining of the 
cells, the Fc receptors on the cells were blocked by incubating the cells for 10 minutes on 
ice with goat anti-IgG (2 mg/ml) (Sigma, St. Louis, MO). Phycoerythrin (PE) conjugated 
monoclonal antibody (Mab) specific for feline CD4 (Southern Biotechnology Associates, 
Birmingham, AL) and fluorescein isothiocyanate (FITC) conjugated Mab specific for 
feline CD8β chain (Southern Biotechnology Associates, Birmingham, AL) were then 
added to the cells in the respective tubes at a final dilution of 1:50. After incubating for 
30 minutes on ice, the cells were washed once with cold PBS-0.1% sodium azide and 
centrifuged at 1200 rpm for 10 minutes (Jouan Inc., Winchester, VA). Negative controls 
consisted of unstained cells. After washing the cells, 300 ul of 2% formaldehyde were 
added to the tubes, which were wrapped in an aluminium foil and kept at 4oC until they 
were examined the next day with a FACscaliber flow cytometer (Becton-Dickinson, San 
Jose, CA) at the Veterinary Pathobiology Core Facility, (Director, Dr. Roger Smith, 
Texas A&M University, College Station). 
  Lymphocytes were analyzed on a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA), using CellQuest (Becton Dickinson) acquisition software. 
Green fluorescence from conjugated fluorescein was analysed through a 530/30-nm 
bandpass filter, and orange fluorescence from R-phycoerythrin through a 585/42-nm 
bandpass filter. Electronic compensation was applied to correct for spectral overlap of 
fluorescein and R-phycoerythrin during data acquisition.  List mode data were acquired 
on a minimum of 10,000 cells defined by light scatter gates. Data analysis was performed 
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in CellQuest / FlowJo, (Treestar, Inc., Palo Alto, CA) using forward and side light scatter 
to gate on the lymphocyte population. 
 
Virus isolation  
Fresh PBMC from weeks 2, 4, 7 and 9 p.i. were cultured as described previously 
with RPMI 1640 (Gibco BRL, Grand Island, N.Y.) supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (Atlas Biologicals, Fort Collins, CO), 50 ug/ml of 
gentamicin (Gibco BRL, Grand Island, N.Y.), 5 x 10-5 M 2-mercaptoethanol (Gibco 
BRL, Grand Island, N.Y.), 2mM L-glutamine (Gibco BRL, Grand Island, N.Y.) and with 
5 ug/ml of Concavalin A (Con A) (Sigma, St. Louis, MO) for 3 days. Cells were grown 
at 37oC in a humidified atmosphere of 5% CO2. On the third day, the cells were washed 
and cultured in complete RPMI containing 100 U human recombinant interleukin -2 (hr 
IL-2) per ml (Gibco BRL, Grand Island, N.Y.). Thereafter, virus replication was 
monitored every 3 days using the FIV capsid antigen ELISA.  
  
PCR amplification of proviral DNA 
  In order to amplify the proviral DNA, genomic DNA was isolated from 1 ml of 
blood collected at 2, 4, 7 and 9 weeks p.i. using using red blood cell lysing buffer and 
QIAmp DNA blood mini kit (Qiagen Inc., Valencia CA). In addition, genomic DNA was 
isolated using QIAmp DNA blood mini kit from PBMC, after culturing for 6 days as 
mentioned above. The DNA was stored at -20oC. FIV capsid gene region was amplified 
by nested PCR using genomic DNA obtained from PBMC of the FIV infected cats and 
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uninfected control cats. The initial PCR used primers 628F (5’-
ATGGGGAACGGACAGGGGCGA-3’) and 1957R (5’-TTATAAATCCAATAGTCT 
CTCCTC-3’) amplifying a 1329 bp gag product, while the second round nested PCR 
used primers 1033F (5’-CCTATTCAAACAGCAAATGGAGCA-3’) and 1678R (5’- 
TGGCAAGAGTTGCATTTTATATCCTGG-3’) amplifying a 645 bp gag product. 
Primers used in this study were made by IDT, Inc. (Coralville, IA). The following 
parameters were used for the primary amplification of the gag gene product using a 
GeneAmp 2400 (Perkin Elmer, Norwalk, CT): 94oC for 5 min, followed by 5 cycles of 
94oC for 60s, 53o C for 60s and 72oC for 2 min., and finally 30 cycles of 94oC for 15s, 
53o C for 45s and 72o C for 2 min. The annealing step was increased by 0.1oC per cycle 
for 30 cycles. The reaction was held at 72oC for 15 min followed by 4o C for infinity. 
The thermal cycling parameters for the secondary amplification were identical to the 
primary amplification except that 5 ul of the each of the primary PCR products was used 
as template. 
 
Anti-FIV capsid antibody assay 
Detection of antibodies against FIV-TX53 in plasma from each blood collection 
was evaluated using the IDEXX Petcheck anti-capsid antibody ELISA kit (IDEXX Inc., 
 Portland, ME).  
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Statistical analysis 
 The data obtained from the experiment designed to study the pathogenesis of 
FIV-TX53 isolate was analyzed using a repeated measures design (Kuehl, 2000). The 
analysis determined if there was a significant difference in the response variables 
(Absolute CD4+ T cells, absolute CD8+ T cells, CD4+/CD8+ T cell ratio, numbers of 
lymphocytes and neutrophils, percentages of CD8βlow and CD8βhigh expression) with 
respect to the three doses of virus inoculum administered (treatment) and over the weeks 
that it was examined (time). The repeated measures design was preferred since it 
accounted for trends in the response variables across the different time points and 
treatment levels. If a significant difference was observed in the main effects for 
treatment or time, pairwise comparisons between various doses or pairwise comparisons 
between different weeks were carried out using Tukey test for pairwise comparison of all 
treatment means (Kuehl, 2000). Statistical significance was set at p < 0.05. In order to 
compare the results obtained for the infected cats with respect to the control uninfected 
cats, Dunnett’s method for comparison of all treatments with a control was used (Kuehl, 
2000). This test determined if there was a significant difference (p< 0.05) between the 
three viral doses and the control across all the weeks examined. In order to establish 
significant differences between the responses for the control uninfected cats and the data 
values obtained for the cats infected with three doses of the virus for each week, a one 
way analysis of variance (ANOVA) was performed. Using ANOVA, pairwise 
comparisons were carried out using least significant difference test (LSD), Tukey test 
which is also called honestly significant difference (HSD) test, Student-Newman-Keuls 
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(SNK) multiple range test and Dunnett’s method for comparison of all treatments with a 
control (Kuehl, 2000). Statistical significance was again set at p < 0.05. All the statistical 
analysis was performed using the SAS software (SAS Institute, Cary, NC). 
 
RESULTS 
Clinical illness 
 Four-month-old cats were infected with three different doses of the FIV-TX53 
isolate. Cats in each group developed a mild to moderate generalized lymphadenopathy 
of their popliteal or submandibular lymph nodes starting around 10 days p.i. 
Surprisingly, all the cats infected with 2000 TCID50 of the virus demonstrated 
lymphadenopathy while only one cat from each group of cats infected with either 500 
TCID50 (cat 3819) or 8000 TCID50 (3825) of the virus demonstrated lymphadenopathy. 
There was no significant difference in the timing of lymphadenopathy among the three 
groups of cats infected with the varying doses of the virus. Except for the 
lymphadenopathy, the cats appeared to be normal. 
 
Complete blood cell evaluations 
 Hematologic abnormalities were observed in the infected cats as compared to the 
uninfected cats. Complete blood counts indicated that the number of lymphocytes and 
neutrophils did decrease over time p.i., but with some exceptions did not fluctuate as 
compared with the counts of sham infected control cats. Lymphopenia seen by 7 weeks 
p.i. for cat 3821 (500 TCID50 of the virus) persisted until 11 weeks p.i. (Fig. 8). Cat 3822 
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(2000 TCID50 of the virus) showed lymphopenia between weeks 7 and 9 p.i. and the 
numbers returned to normal values by 11 weeks p.i. Cat 3824 from the same group also 
receiving 2000 TCID50 of the virus was lymphopenic at 11 weeks p.i. (Fig.8). For all 
doses of virus administered, the number of lymphocytes at 4 weeks p.i. was statistically 
greater than at 9 weeks p.i. (p < 0.05) (Fig. 8).  Surprisingly, the cats infected with 8000 
TCID50 of the virus were not lymphopenic at any of the times examined. The absolute 
lymphocytes of the sham infected control cats were within the normal range at all times 
examined. 
 The number of neutrophils after infection was statistically lower than preinfection 
values, at weeks 2 (p = 0.0095), 4 (p = 0.0.0314), 7 (p = 0.0292), 9 (p = 0.0002) and 11 
(p = 0.0056) p.i. for all viral doses administered (Fig. 9). Interestingly, all three cats 
infected with 500 TCID50 of the virus demonstrated neutropenia either at week 11 p.i. 
(Cat 3819), or at week 9 p.i. (Cat 3820) while cat 3821 continued to show a reduction in 
the neutrophil numbers as compared to normal values between 7 to 11 weeks p.i. (Fig. 
9). In addition between 7 and 11 weeks p.i., neutrophil numbers were decreased in two 
cats infected with 2000 TCID50 of the virus (cats 3822, 3824) as compared with those 
from sham inoculated controls (Fig. 9). The decline in neutrophil numbers of cats 
infected with 8000 TCID50 was not statistically different from that of the normal 
neutrophil values at any time examined. Therefore, no trend was observed between the 
amount of virus administered and decrease in the absolute numbers of neutrophils or 
lymphocytes, for the uninfected and infected cats.  
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Fig. 8. Absolute blood lymphocyte counts until 11 weeks after infection of cats with varying doses of FIV-
TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected i.v. 
with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the virus 
and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus.  
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Fig. 9. Absolute blood neutrophil counts until 11 weeks after infection of cats with varying doses of FIV-
TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected i.v. 
with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the virus 
and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus. 
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CD4+/CD8+ T lymphocyte ratios  
 The CD4+/ CD8+ T cell ratio was determined for the cats before they were 
infected and at 2, 4, 7, 9 and 11 weeks p.i. A temporal decrease in the CD4+/ CD8+ T cell 
ratio could be observed for the infected cats depending on the viral dose administered as 
compared to the uninfected cats. Thus, the CD4+/ CD8+ T cell ratio of the cats dropped 
below 1 between weeks 4-7 p.i. for cats infected with the highest dose (TCID50 = 8000) 
of the virus (Fig. 10). Two of the three cats (cats 3822 and cat 3823) infected with 2000 
TCID50 of virus inoculum showed a CD4+/ CD8+ T cell ratio below 1 at week 9 p.i., 
while the ratio was below 1 for the third cat from the same group (cat 3824), at week 7 
p.i. The CD4+/ CD8+ T cell ratios for two of the cats 3819 and 3821, infected with the 
least amount of virus (TCID50 = 500) dropped below 1 by only 11 weeks p.i. The CD4+/ 
CD8+ T cell ratios of the cats infected with any of the three doses of the virus were 
significantly lower than those of the uninfected cats at weeks 7, 9 and 11 p.i. (p < 0.01) 
(Fig. 10).   
 For all the times examined, the decrease in the CD4+/CD8+ T cell ratio was 
accompanied by a temporal and sharp decline of CD4+ T cells, which remained low even 
at 11 weeks p.i. and did not revert to the preinfection levels except for cat 3820 at 11 
week p.i. (Fig. 10 and 11). This decline in the number of CD4+ T cells was not found to 
depend on the dose of the virus inoculum administered (Fig. 11). However, there was a 
significant reduction in the numbers of CD4+ T cells of cats infected with either 500 or 
2000 TCID50 of the virus at all times examined, as compared to the uninfected controls 
(p < 0.05). The numbers of CD4+ T cells were significantly reduced at week 11 p.i. as 
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compared to week 4 p.i. (p = 0.0417) and at week 9 p.i. as compared to the CD4+ T cell 
numbers before infection (p = 0.0086),  at weeks 2 (p = 0.0128) and 4 (p = 0.0047) p.i. 
for all the doses of virus administered.  
 The decline in the CD4+/CD8+ T cell ratio was also accompanied by a 
corresponding small increase in the number of CD8+ T cells (Fig. 10 and 12). The 
absolute numbers of CD8+ T cells did show a significant difference depending on the 
virus dose administered (p = 0.029) and over the weeks examined (p = 0.0321). However 
the small sample number of the cats prevented pairwise significant differences to be 
detected using the Tukey test (Kuehl, 2000). The absolute CD8+ T cell numbers for cats 
infected with the highest dose of the virus (TCID50= 8000) was significantly greater than 
CD8+ T cell numbers of uninfected cats at all the times examined (p < 0.05) (Fig. 12). 
Absolute CD8+ T cell numbers in cats infected with 500 TCID50 or 2000 TCID50 of the 
virus increased very slightly as compared to pre-infected values (Fig. 12). However this 
slight increase in the numbers of CD8+ T cells from cats infected with either 500 or 2000 
TCID50 was not significantly high as compared to CD8+ T cell numbers of sham 
inoculated control cats at all times examined. 
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Fig. 10. CD4+/ CD8+ T lymphocyte ratio until 11 weeks after infection of cats with varying doses of FIV-
TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected i.v. 
with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the virus 
and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus.  
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Fig. 11. Absolute CD4+ T lymphocyte counts until 11 weeks after infection of cats with varying doses of 
FIV-TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected 
i.v. with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the 
virus and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus.  
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Fig. 12. Absolute CD8+ T lymphocyte counts until 11 weeks after infection of cats with varying doses of 
FIV-TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected 
i.v. with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the 
virus and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus.  
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Expansion of CD8βlow T lymphocytes in FIV-TX53 infected cats 
 In our studies, the increase in the numbers of CD8+ T cells of the infected cats 
was accompanied by an expansion of a CD8βlow T cell population, as indicated by flow 
cytometry using Mab to feline CD8β chain (Southern Biotechnology Associates, 
Birmingham, AL). The representative contour and dot plots in Fig. 13 demonstrate 
typical patterns of CD8β chain expression on fresh PBMC from uninfected cat 3828 and 
cat 3824 infected with 2000 TCID50 of the virus at 7 weeks p.i. In contrast to FIV 
uninfected cats, CD8β chain expression on fresh PBMC from FIV infected cats was 
bimodal, demonstrating the presence of two distinct subpopulations of CD8+ T cells, 
CD8βlow and CD8βhigh. The CD8βlow population of CD8+ T cells increased as infection 
progressed, reaching peak levels at 9 weeks p.i. (Fig.14). The percentages of this 
CD8βlow population for all infected cats, started increasing by 4 week p.i. but were 
significantly increased by weeks 9 (p = 0.0113) and 11 p.i. (p = 0.0002) as compared to 
the sham infected control cats (Fig. 14). There was no trend observed between the 
amount of virus administered and the temporal increase of this population.  
However, there was a significant difference seen in the percentages of the 
CD8βhigh T cells depending on the virus dose administered (p = 0.0455) (Fig. 15).  
However due to the small sample size, significant pairwise differences (p = 0.0312) 
could be observed only between the percentages of CD8βhigh T cells from cats infected 
with 2000 TCID50 or 8000 TCID50 of the virus. Thus, the percentages of CD8βhigh 
population were significantly increased (p < 0.05) in cats infected with 8000 TCID50 of 
the virus as compared to cats infected with 2000 TCID50 of the virus and sham infected  
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Fig. 13. Patterns of CD8βlow expression. Patterns of CD8βlow expression for FIV uninfected cat 3828 (A1 
and A2) and cat 3824 (B1 and B2) infected with 2000 TCID50 of FIV-TX53 virus at 7 weeks p.i. Contour 
plots (A1 and B1) or dot plots (A2 and B2) presented as fluorescence intensity are shown. 
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Fig. 14. Expansion of the CD8βlow subset of T lymphocytes until 11 weeks after infection of cats with 
varying doses of FIV-TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 
3821 were infected i.v. with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 
2000 TCID50 of the virus and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus. 
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Fig. 15. The CD8βhigh subset of T lymphocytes until 11 weeks after infection of cats with varying doses of 
FIV-TX53 virus. Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected 
i.v. with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were infected i.v. with 2000 TCID50 of the 
virus and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus. 
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control cats across all the weeks examined (Fig. 15). Surprisingly, the percentages of 
CD8βhigh population were significantly decreased (p < 0.05) for cats infected with 2000 
TCID50 of the virus as compared to the sham infected control cats across all the weeks 
examined. There was no significant change in the percentages of CD8βhigh population for 
cats infected with 500 TCID50 of the virus, when compared to the sham infected control 
cats (Fig. 15). 
 
Virus isolation and nested PCR for provirus detection 
Virus could be detected after culturing PBMC at 9 weeks p.i. for all the infected 
cats, but virus isolation took longer for PBMC collected at 2, 4 and 7 weeks p.i. By day 
9 of culture, PBMC supernatants collected at 2 weeks p.i. from the three cats infected 
with the highest dose (8000 TCID50) were positive for the presence of FIV capsid 
antigen by FIV antigen capture ELISA (Table 2). By day 9 of culture, supernatants from 
PBMC collected at 2 weeks p.i. from two of the three cats (cat 3823 and cat 3824) 
infected with 2000 TCID50 of the virus were positive while none of the PBMC 
supernatants from cats receiving the lowest dose of the virus (500 TCID50) were positive 
(Table 2). After an additional 5 days of culture, PBMC from all the cats were positive by 
FIV capsid ELISA except for cat 3820 receiving only 500 TCID50 of virus. However, 
PBMC supernatants from cat 3820 were positive for viral antigen following an 
additional 7 days of culture. For PBMC collected 4 weeks p.i., three cats in the group 
infected with the lowest dose of the virus and one cat each from the groups infected with 
either middle or highest dose of the virus were negative by FIV capsid ELISA on the 9th 
 Table 2 
Evaluation of virus isolated from peripheral blood of cats inoculated with varying doses of FIV-TX53 virus 
    2 wpi 4wpi 
  PCR Virus Isolation  PCR Virus Isolation  
TCID50 
OF FIV-
TX53 
VIRUS  CATS
From 
fresh 
PBMC 
From 
cells 
cultured 
for 6 
days 
After 9 
days 
of 
culture 
After 14 
days of 
culture 
Capsid 
Antibody 
detection
From 
fresh 
PBMC 
From 
cells 
cultured 
for 6 
days 
After 9 
days of 
culture 
After 14 
days of 
culture 
Capsid 
Antibody 
detection
500  3819 − − − + − − + − + − 
          
  
         
  
          
  
          
      
          
      
           
    
          
      
          
      
  
3820 − − − + (21  days)
 
− − − − + − 
  
3821 − + − + − − + − + − 
  
2000 3822 − + − + − − + − + + 
  
3823 + + + − + + + + 
  
3824 − − + − + + + − 
 
8000 3818 − + + − − − − + + 
  
3825  − + + − − − + + 
  
3829 − − + − − + + + 
 
Cats 3826, 3827 and 3828 were uninfected controls, cats 3819, 3920, 3821 were infected i.v. with 500 TCID50 of the virus, cats 3822, 3823 and 3824 were 
infected i.v. with 2000 TCID50 of the virus and cats 3818, 3825 and 3829 were infected i.v. with 8000 TCID50 of the virus. The uninfected control cats tested 
negative for virus isolation by culture and PCR and were seronegative for the 9 weeks examined 
 
100
 Table 2 (continued) 
    7 wpi 9 wpi 
      PCR Virus isolation PCR
Virus 
Isolation   
TCID50 
OF FIV-
TX53 
VIRUS  CATS
From 
fresh 
PBMC 
From 
cells 
cultured 
for 6 
days 
After 9 
days of 
culture 
After 14 
days of 
culture 
Capsid 
antibody 
detection
From 
fresh 
PBMC 
From 
cells 
cultured 
for 6 
days 
After 9 
days of 
culture 
Capsid 
antibody 
detection
500  3819 − − − + + − + + + 
          
    
          
  
          
  
          
    
          
    
          
  
          
    
          
  
 
3820 − + + + + + + + 
 
3821 − + − + + + + + + 
 
2000 3822 − + − + + + + + + 
 
3823 + + + + + + + + 
 
3824 + + + + + + + + 
 
8000 3818 − + − + + + + + + 
 
3825 − + + + − + + + 
 
3829 − + − + + + + + + 
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day of culture, but were positive by day 13 of culture (Table 2). PBMC collected at 7   
weeks p.i. from all the infected cats were positive for the presence of FIV capsid by 
ELISA by day 14 of culture. PBMC collected at 9 weeks p.i. from all the cats regardless 
of viral dose administered initially, were positive by FIV capsid ELISA after only 9 days 
of culture. PBMC from uninfected cats were consistently negative by ELISA at all times 
examined (Table 2). 
In agreement with results obtained for virus isolation, provirus detection for the 
capsid region of the virus was sporadic by nested PCR using genomic DNA (gdna) 
obtained from freshly collected PBMC at 2, 4 and 7 weeks p.i. At 2, 4 and 7 weeks p.i., 
fresh gdna from only cats 3823 or 3824 (2000 TCID50) tested positive by PCR (Table 2). 
However, gdna from PBMC of infected cats 3818, 3819, 3820, 3821, 3822, 3825 and 
3829 tested positive after 6 days of culture (Table 2). As shown in Table 2, at 9 weeks 
p.i., gdna obtained from freshly collected PBMC from all the infected cats, except cat 
3819 (500 TCID50) and cat 3825 (8000 TCID50) tested positive by nested PCR. Thus, an 
increase in the virus load by 9 weeks p.i. could be deduced by the increased frequency of 
the virus isolation from fresh PBMC both by ELISA and by nested PCR (Table 2). The 
sham infected control cats were also consistently negative for FIV gag by nested PCR. 
 
Seroconversion 
 The FIV uninfected control animals remained seronegative for antibodies to FIV 
capsid throughout the course of the experiment as indicated in Table 2. Capsid 
antibodies could not be detected from plasma at 2 weeks p.i. for any of the infected cats 
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(Table 2). Antibodies could be detected in plasma by 4 weeks p.i from all the three cats 
infected with the highest dose of the virus (8000 TCID50), two of the cats infected with 
(2000 TCID50) and none of the cats infected with the least dose of the virus (Table 2). 
By 7 week p.i. all the cats infected with the lowest dose of virus (500 TCID50) and the 
third cat infected with 2000 TCID50 had also seroconverted. The cats did not become 
seronegative with antibodies persisting in all the infected cats at least until 9 weeks p.i.  
(Table 2). 
 
DISCUSSION 
  Previous studies from our laboratory indicated that FIV isolates obtained from 
naturally infected feral cats in Texas clustered separately from the other known clades of 
FIV, though it was more similar to viruses from FIV clade B (Weaver et al., 2004). The 
objective of the present study was to characterize the acute stage of infection by 
experimental infection of SPF cats with a biological clone of a Texas isolate namely; 
FIV-TX53 and to determine the dose response effects of virus infection.   
 Various strains of FIV have been examined for their pathogenicity in 
experimentally infected cats, though different routes of inoculation and various doses of 
virus used prevent absolute comparisons. Infections with FIV-A-PPR and FIV-A-
Petaluma are thought to cause a milder disease as compared to FIV-A-NCSU1, FIV 
clade B and C field isolates that have been shown to cause fatal immunodeficiency 
disease in cats under experimental conditions (Burkhard et al., 2002; Diehl et al., 1995b; 
Elder et al., 1998;  Sparger et al., 1994).  
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 The Texas isolates appear to share a common ancestor with isolates from FIV 
clade B (Weaver et al., 2004). Contrasting results for pathogenicity of three clade B viral 
isolates namely FIV subtype B strain 2542, FIV-B-TM1 and FIV-B-TM2, have been 
reported (Burkhard et al., 1997; Kohmoto et al., 1998; Yamamoto et al., 1997). FIV 
subtype B strain 2542 has been shown to be readily transmitted by prenatal and post 
natal mother-to-offspring transmission or by exposure of vaginal and rectal mucous 
membranes to cell associated or cell-free virus and by i.v. inoculation (Burkhard et al., 
2001; Burkhard et al., 2002; O'Neil et al., 1996). Rapid serial passage of acute phase 
plasma from cats infected with FIV-B-2542 induced clinical immunodeficiency, leading 
to lymphadenopathy and inversion of CD4+/ CD8+ T cell ratios (Diehl et al., 1995a). In 
contrast, infection with subtype B strains TM1 and TM2 did lead to immunologic 
abnormalities, such as loss of T cell responses to mitogen stimulation and decreases in 
CD4+/CD8+ T cell ratios by 135 and 160 weeks p.i. (Yamamoto et al., 1997) but clinical 
disease did not appear until 8 years p.i. (Kohmoto et al., 1998).  
 Infection of 4 month old cats with 500, 2000, and 8000 TCID50 of the FIV-TX53 
viral strain did not lead to a fatal disease, although the cats did demonstrate transient 
lymphadenopathy. Complete blood counts indicated that the number of lymphocytes and 
neutrophils did decrease over time p.i., but with some exceptions fluctuated slightly from 
the normal values of sham infected control cats. Our results were similar to those 
obtained for experimental infection with FIV-Petaluma where the lymphocyte and 
neutrophil number dropped between 4 to 6 weeks p.i. (Yamamoto et al., 1988).  
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All the animals in our study had seroconverted by 7 weeks p.i. with 2 of the 3 
cats in the 2000 TCID50 and 3 of the 3 cats in 8000 TCID50 group seroconverting by 4 
weeks p.i. Similar to the time of seroconversion in our studies, comparisons of infection 
in cats by FIV-C-PGammer, FIV-A-Petaluma and FIV-NCSU1 demonstrated that all the 
infected cats had seroconverted by 4 weeks p.i. (English et al., 1994; Pedersen et al., 
2001; Yamamoto et al., 1988), while in another study, cats infected with FIV-PPR or 
FIV-B-2542 had seroconverted by 3 weeks p.i.(Burkhard et al., 2002). Studies by 
Burkhard et al. (2002) which compared provirus levels in PBMC DNA, demonstrated 
that PBMC proviral levels were lower in FIV-A-PPR infected cats at 3 and 6 weeks p.i., 
but were similar to those seen in cats infected with more pathogenic FIV-B-2542 isolate 
by 9 weeks p.i. Although we did not calculate viral titers, the increased frequency of 
virus isolations from all the infected cats, suggested an increase in the viral load in the 
peripheral blood by 9 weeks p.i.  
In our studies, the timing of the inversion of the CD4+/CD8+ T cell ratio in the 
infected cats was found to depend on the amount of virus administered, with CD4+/CD8+ 
T cell ratio dropping below 1 by 11 weeks p.i for eight of the nine infected cats. This 
inversion of CD4+/CD8+ T cell ratio was accompanied in all cases by a corresponding 
decrease of absolute CD4+ T cells for all the viral doses administered. The numbers of 
CD4+ T lymphocytes did not revert to their pre-infection values, except for cat 3820 at 
11 week p.i. A corresponding increase in the CD8+ T cells could be demonstrated for all 
the cats though this increase was significant only for the cats infected with the highest 
dose of the virus as compared to the uninfected cats for all the times examined. Our 
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studies were similar to infection with FIV-A-GL8 biological clone, FIV-A-NCSU1 
biological clone and FIV-B-2542, that led to a decline in the CD4+/CD8+ T cell ratio 
between 3 to 6 weeks p.i. due to decrease in CD4+ and an increase in CD8+ T cell 
numbers (Burkhard et al., 2002; English et al., 1994; Hosie et al., 2002). Although there 
were only three cats in each group in our study, and the timing of change in the 
neutrophil numbers or CD4+ or CD8+ T cell numbers was somewhat variable, strong 
trends were nonetheless evident. 
The increase in the numbers of CD8+ T lymphocytes was accompanied by an 
increase in a subset of CD8+ T lymphocytes expressing low levels of the CD8β chain. 
Expansion of this population has also been demonstrated with experimental infection of 
cats with FIV-A-GL8, FIV-NCSU1 isolate, FIV-A- Petaluma, Swiss isolate of FIV (FIV 
Z2) and FIV-B-TM2 isolate (Bucci et al., 1998b; Lehmann et al., 1992; Shimojima et al., 
1998; Willett et al., 1993). These CD8βlow cells have been defined as CD8α+βlow , with 
the vpg9 and FT-2 antibodies used in the previous studies shown to recognize the CDαβ 
heterodimer and the β-chain of the αβ heterodimer, respectively (Shimojima et al., 
1998).  Although not examined in this study, Bucci et al. (1998b) and Shimojima et al. 
(1998) found that analysis of CD8 α chain expression using anti-CD8 α chain specific 
antibody did not show a reduction in the expression of the CD8 α chain similar to that 
seen for the β chain of CD8.  
Our results are in agreement with those of Willett et al. (1993) in that 
development of cell associated viremia was followed by the appearance of CD8βlow 
population of T cells. In agreement with their studies using FIV-A-GL8 virus, the 
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CD8βlow population of T cells in our studies expanded rapidly after infection, as early as 
4 weeks p.i. In cats infected with the FIV-A-NCSU1 virus, the CD8α+βlow phenotype 
increased in cats before seroconversion during acute infection and became the 
predominant population in asymptomatic, long term infected cats (Bucci et al., 1998b). 
In our studies we observed a significant increase in the CD8βlow population of T cells in 
the acute stage of infection, which increased significantly over time in all the FIV 
infected cats regardless of the viral dose administered. However, the correlation between 
the CD8+ T cell antiviral activity against FIV and the presence of the unique CD8α+βlow 
phenotype in cats has been controversial. Bucci et al. (1998b) have shown that the 
unique CD8α+βlow and not the CD8α+βhigh phenotype, detected as early as 6 weeks p.i., 
correlated with decreased plasma and PBMC-associated viremia and was responsible for 
suppression of FIV-A-NCSU1 in acute and long-term asymptomatic infection. In 
contrast, both CD8high and CD8low T cell subpopulations from PBMC of FIV-GL8 
infected cats were shown to suppress FIV replication in vitro (Flynn et al., 2002). 
Identifying whether CD8βlow or the CD8βhigh population in our infected cats contributes 
to antiviral activity against FIV would be helpful in understanding the mechanism used 
by CD8+ T cells from FIV-PPR cats in our system to suppress FIV-PPR replication in 
vitro. Previous studies from our laboratory have demonstrated an inverse correlation 
between the CD8+ T cell mediated suppressing activity and the proviral load in cats 
chronically infected with the FIV-PPR strain (Unpublished data from our laboratory). 
Crawford et al. (2001) demonstrated that CD8α+βlow cells in the thymus of 
neonatal cats infected with FIV-A-NCSU1 isolate, were linked to a proportional decline 
 
 108
in the CD8α+βhigh cells among a stable number of total CD8α cells, suggesting that 
CD8α+βlow cells might be generated at the expense of CD8α+βhigh cells. In our studies, 
the percentages of CD8βhigh population were significantly decreased (p < 0.05) for cats 
infected with 2000 TCID50 of the virus as compared to the control-uninfected cats across 
all the weeks examined. Since the decrease in the percentages of CD8βhigh population for 
cats 3823 and 3824 infected with 2000 TCID50 of the virus coincided with their 
percentages of CD8βlow population increasing, it is tempting to speculate that CD8βlow 
population is increasing at the expense of the CD8βhigh population. 
  In conclusion, we have shown that infection of cats with FIV-TX53, which 
belongs to a newly emerging subtype, causes acute disease characterized by a decline of 
CD4+/CD8+ T cell ratios below 1 by 11 weeks p.i. This reduction was marked by rapid 
changes in the lymphocyte profiles of the cats, which included an expansion of the 
CD8βlow population of CD8+ T cells.  
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CHAPTER V 
 
VARIATION IN THE V3-V4 ENVELOPE SEQUENCE FROM FELINE 
IMMUNODEFICIENCY PROVIRUS OBTAINED FROM BLOOD, SPLEEN 
AND LYMPH NODES OF CATS EXPERIMENTALLY INFECTED WITH THE 
FIV-PPR MOLECULAR CLONE 
 
INTRODUCTION 
  A major obstacle in the development of a vaccine against human 
immunodeficiency virus (HIV) has been the high plasticity of its genome (Coffin, 1986; 
Temin, 1989). Lentiviruses, such as HIV and simian immunodeficiency virus (SIV), 
display a large degree of molecular and biological variation. This rapid evolution is 
generally attributed to the low fidelity of the viral enzyme reverse transcriptase (RT) in 
copying the viral genomic RNA to DNA (Mansky and Temin, 1995; Roberts et al., 
1988). HIV-1 genome exhibits extensive sequence variation, both between patients, 
within different tissues of an individual patient and even within different regions of the 
same tissue (Ball et al., 1994; Casado et al., 2001; Chang et al., 1998; van't Wout et al., 
1998; Visco-Comandini et al., 2001).  
Feline immunodeficiency virus (FIV) has been reported worldwide with a 
prevalence rate ranging from 1-28% (Ishida et al., 1989; Yamamoto et al., 1989). FIV 
was first isolated from a cat with symptoms of an immunodeficiency like syndrome in 
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1986 (Pedersen et al., 1987). Like HIV-1, FIV can induce immunological abnormalities, 
including an inversion in the CD4+/CD8+ T cell ratios resulting from a decrease in CD4+ 
T cells (Ackley et al., 1990; Hoffmann-Fezer et al., 1992; Novotney et al., 1990) and 
decreased lymphocyte proliferative responses to mitogens (Barlough et al., 1991; 
Siebelink et al., 1990; Torten et al., 1991). Such similarities in biological behavior 
between HIV-1 and FIV, support FIV infection of cats as a small-animal model to study 
the pathogenesis of lentivirus induced AIDS and as a model for the HIV vaccine 
development.  
Similar to the envelope (env) gene of HIV, Pancino et al. (1993b) have identified 
nine variable regions throughout the FIV env gene. The first two are located in the leader 
region, which is also the first coding exon of the rev gene and are not present in the 
mature env protein because of proteolytic processing (Pancino et al., 1993b; Phillips et 
al., 1992; Verschoor et al., 1993). Variable regions V3 through V6 occur in the surface 
protein (SU), and variable regions V7 through V9 occur in the transmembrane protein 
(TM) (Pancino et al., 1993b). The V3 region of the SU in addition to the ectodomain of 
the TM glycoprotein (Vahlenkamp et al., 1997) has been found to be responsible for the 
tropism of FIV for Crandell feline kidney (CRFK) cells (Siebelink et al., 1995b; 
Verschoor et al., 1995). Macrophage tropism of FIV is dictated by the V3 and V4 
regions of the env gene (Vahlenkamp et al., 1999). The V3 region also contains a linear 
neutralization domain (de Ronde et al., 1994; Lombardi et al., 1993b) that is involved in 
the neutralization of CRFK cell adapted FIV strains while V4 and V5 regions were 
found to be necessary for FIV neutralization in feline thymocytes (Siebelink et al., 
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1995a). Cell culture adapted strains of FIV are able to use CXCR4 to facilitate cell 
fusion mediated through the V3 region (Willett et al., 1997b; Willett et al., 1997c).  
An important feature of the FIV model is the availability of molecular clones 
that, after transfection into cells in culture, give rise to infectious virions (Hosie et al., 
2002; Miyazawa et al., 1991; Phillips et al., 1990; Siebelink et al., 1992; Talbott et al., 
1989). FIV derived in this manner can be used for experimental inoculation of cats and 
the fate of a single FIV clone, as it replicates over time in the infected host can be 
determined. The use of a molecularly cloned virus allows genetically homogenous viral 
populations to be obtained. This provides unique opportunities to study both viral 
evolution within a host and the generation of tissue specific variants by eliminating 
factors, such as a mixed inoculum of viral variants differing in their cellular tropism. 
Relating the biological properties of such populations to the genomic structure of the 
molecular clone, from which they were derived, could reveal the basis of biological 
variation and may identify determinants of viral virulence.  
The level of intra-sample and intra-individual variation, of the FIV env gene 
during the course of infection and the effect of host factors, such as immune pressure on 
the extent of variation, can have a great influence on the pathogenesis of the disease 
caused by FIV (Dean et al., 1999; Hosie et al., 2002; Sodora et al., 1995; Sodora et al., 
1994). In this chapter, results of a study involving V3-V4 env sequence variation among 
three tissues from six FIV infected cats have been presented.  
 
 
 
 112
MATERIALS AND METHODS 
Experimental animals 
 Specific, pathogen-free (SPF) cats purchased, from Harlan Sprague-Dawley, 
Madison, WI or Liberty Laboratories, Liberty Corner, N.J., were serologically negative 
for feline leukemia virus. Cats were housed in a specific, pathogen-free environment at 
the Laboratory Animal Research and Resources Support Facility (LARR), Texas A&M 
University, College Station. Cats A306, A308, M153, M160, M165 and M242 had been 
experimentally infected i.v. with 50 TCID50 (cats M153, M160, M165 and M142) or 250 
TCID50 (cats A306 and A308) of FIV-PPR molecular clone (Table 3) prepared as 
described elsewhere (Hokanson et al., 2000). The six cats were humanely euthanized 3 
to 6 years post infection (p.i.) by intravenous (i.v.) injection of three milliliters of 
concentrated pentobarbital sodium solution (390 mg/ml). Prior to euthanasia, blood was 
collected in EDTA (K3)-treated tubes. Complete blood counts were performed by Texas 
Veterinary Medical Diagnostic Laboratory, College Station, Texas. Lymph nodes and 
spleen tissues collected at necropsy were rapidly frozen and stored at -80oC for 
subsequent DNA analysis.  
 
Antibodies  
Monoclonal antibodies (Mab) to feline CD4 conjugated to phycoerythrin (PE) 
(Southern Biotechnology Associates, Birmingham, AL) and Mab to feline CD8β chain   
conjugated to fluorescein isothiocyante (FITC) (Southern Biotechnology Associates, 
Birmingham, AL) were purchased commercially. 
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Table 3 
 History of the cats infected with the FIV-PPR molecular clone 
Cats FIV Dose TCID50
Sex Age at euthanasia Year Infected 
M153 50 F 4 years 5 months 2000 
M160 50 M 4 years 5 months 2000 
M165 50 F 4 years 5 months 2000 
M242 50 M 4 years 5 months 2000 
A306 250 M 6 years 1997 
A308 250 M 6 years 1997 
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Phenotypic characterization of freshly prepared peripheral blood mononuclear cells 
(PBMC) 
PBMC from FIV infected cats A306, A308, M160, M165 and M24 were isolated 
from EDTA (K3)-treated whole blood by Histopaque-1077 (Sigma, St. Louis, MO) 
density gradient centrifugation (Choi et al., 2000b) and washed once with cold 
phosphate-buffered saline (PBS) containing 0.1% sodium azide. Prior to staining of the 
cells, the Fc receptors on the cells were blocked by incubating the cells for 10 minutes on 
ice with goat anti-IgG (2 mg/ml) (Sigma, St. Louis, MO). PE conjugated Mab to feline 
CD4 and FITC conjugated Mab to feline CD8 β chain were then added to the cells in the 
respective tubes at a final dilution of 1:50. After incubating for 30 minutes on ice, the 
cells were washed once with cold PBS-0.1% sodium azide and centrifuged at 1200 rpm 
for 10 minutes (Jouan Inc. Winchester, VA). Negative controls consisted of unstained 
cells. After washing the cells, 300 ul of 2% formaldehyde were added to the tubes, which 
were wrapped in an aluminium foil and kept at 4oC until they were examined the next 
day with a FACscaliber flow cytometer (Becton-Dickinson, San Jose, CA) at the 
Veterinary Pathobiology Core Facility, (Director, Dr. Roger Smith, Texas A&M 
University, College Station). 
 
Genomic DNA isolation 
 Feline PBMC were isolated from EDTA (K3)-treated whole blood by 
Histopaque-1077 (Sigma, St. Louis, MO) density gradient centrifugation (Choi et al., 
2000b). Genomic DNA was extracted from PBMC using QIAmp DNA blood mini kit 
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(Qiagen Inc., Valencia CA). Genomic DNA was also extracted from lymph nodes and 
spleen tissues using the mammalian genomic DNA isolation miniprep kit (Sigma, St. 
Louis, MO). 
 
Cloning of the FIV env V3 through V4 regions 
FIV V3-V4 env gene region was amplified by nested PCR from genomic DNA 
extracted from lymph node and spleen tissues and PBMC of the FIV infected cats. The 
first round PCR used primers 6782F (5’-GCTCAGATAGTATGGAGACTTCC-3’) and 
8814R (5’- ACTCCATCATTCCTCCTCTT-3’) that amplified an 2051bp env product. 5 
ul of the first round PCR reaction were used as a template for the second round PCR that 
used primers 7313F (5’-ATACCAAAATGTGGATGGTG-3’) and 7844R (5’- 
CAAGACCA ATTCCCAGCAAT-3’), which amplified an 551 bp env product spanning 
the V3-V4 region. Primers used in this study were made by IDT, Inc. (Coralville, IA). 
The following parameters were used for the primary amplification of the env gene 
product using a GeneAmp 2400 (Perkin Elmer, Norwalk, CT): 94oC for 5 min, followed 
by 5 cycles of 94oC for 60s, 53oC for 60s and 72oC for 2 min., and finally 30 cycles of 
94oC for 15s, 53oC for 45s and 72o C for 2 min. The annealing step was increased by 
0.1oC for each of the 30 cycles. The reaction was held at 72oC for 15 min followed by 
4oC for infinity. The thermal cycling parameters for the secondary amplification were 
identical to the primary amplification. After purification of the PCR product, using the 
GenElute PCR clean-up kit (Sigma, St. Louis, MO), the samples were cloned into 
pSTBlue-1 vector (Novagen, Madison, WI) and transformed into Novablue Singles 
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competent cells (Novagen, Madison, WI). Recombinant plasmids were checked for the 
presence of insert by colony PCR according to the instructions in the Novagen Acceptor 
Vector kit manual (Novagen, Madison, WI). The plasmids containing the inserts were 
then amplified and purified using the GenElute Plasmid miniprep kit (Sigma, St. Louis, 
MO.).  
 
DNA Sequencing  
Three plasmids were sequenced for each tissue examined from each cat. DNA 
sequencing was carried out using the dye terminator cycle sequencing method (Gene 
technologies Core facility, Texas A&M University). The following thermal cycling steps 
were used for the extension of the V3-V4 product for 45 cycles: 96oC for 10 sec, 50oC 
for 5 sec and 60oC for 4 minutes. All PCR reactions were performed using a GeneAmp 
PCR system 2400 thermal cycler (Perkin Elmer, Norwalk, CT). After purification of the 
product by spin column purification protocol, the samples were sent to the Gene 
Technologies core facility for DNA sequencing (Department of Biology, Texas A&M 
University, College Station, Texas). The clones were sequenced bi-directionally using 
the T7 promoter sequence as the forward primer and the SP6 promoter sequence as the 
reverse primer. 
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Sequence alignment and phylogenetic analyses 
Nucleotide sequences were aligned using the CLUSTAL W multiple sequence 
alignment program (Thompson et al., 1994b) of SDSC biology workbench. All aligned 
sequences were also inspected manually to correct for apparent mistakes. Positions 
containing gaps or ambiguously aligned positions were removed from the data set. 
Phylogenetic trees were established by the neighbor-joining method (Saitou and Nei, 
1987), as well as the maximum likelihood method with similar branching patterns. The 
maximum likelihood method was implemented using PAUP* (D. L. Swofford, PAUP 
4.0, version 4.0b10) and neighbor-joining method was implemented using MEGA 
version 2.1 (Kumar et al., 1994). The statistical value of the tree was evaluated by 
bootstrap analysis of 1000 replicas. Pairwise protein and nucleic acid sequence distances 
were calculated using the CLUSTAL W multiple sequence alignment program of SDSC 
biology workbench. 
 
RESULTS 
Clinical history of the cats 
As indicated in Table 4, the CD4+/ CD8+ T cell ratios at the time of euthanasia 
ranged from 0.2-1.75 for the six cats, which were below the values observed normally 
for FIV uninfected cats. CBC analysis demonstrated few poikilocytosis of the red blood 
cells (presence of abnormally shaped red blood cells) for cats M153 and M160. The total 
number of lymphocytes from the six FIV infected cats was below average (Table 4). The 
neutrophil number was also below average for cats M153, M160 and A308 (Table 4). 
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Data from uninfected cats suggest that in general, CD4+ T cell counts below 200 cells/ul 
are abnormally low (Sodora et al., 1994). According to this criterion, except for cat 
M165, all cats had abnormally low CD4+ T cell levels at euthanasia (Table 4).  
 
 
 
Table 4 
Immunological and hematological characteristics of FIV-PPR infected cats at euthanasia 
Absolute number of cells per ul 
 T cells  Cats 
CD4+/CD8+ T 
cell ratio 
Lymphocytes CD4+ CD8+ Neutrophils 
M153 0.41 728 139 336 1560 
M160 0.2 800 26 130 2208 
M165 1.24 1113 226 183 3551 
M242 1.75 1450 122 70 N.D. 
A306 1.3 279 72 56 2573 
A308 0.38 713 91 238 1380 
 
Normal CD4+ /CD8+ T cell ratio in FIV uninfected cats > 2 
Normal lymphocyte count = 1500-7000 cells/ ul 
Normal CD4+ T cell count > 200 cells/ ul 
Normal neutrophil count = 2500-12500 cells/ ul  
N.D. = not done 
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Records maintained at LARR indicated that cat A306 had mild gingivitis a few days 
before euthanasia and cat M242 had demonstrated extreme neutropenia and vomiting a 
year before it was euthanised. Cats A306 and A308 had also demonstrated vomiting, and 
diarrhea was noted for A308 two months before they both were euthanised. At the time 
of necropsy, cat A308 demonstrated signs of enteritis while cat M153 showed a brain 
lesion.  
 
Sequence analysis 
The V3-V4 env region was amplified as a 551bp product from lymph nodes, 
spleen and PBMC of all the six cats, except from PBMC of cat M153. Nucleotide 
sequences of the env V3-V4 region were obtained from the PCR amplified products. The 
viral variants were assigned numbers according to the number of the bacterial clone 
containing the env insert, followed by the letter indicating the organ from which the 
clones were obtained (L = lymph node, P = PBMC, S = spleen) followed by the name of 
the cat. Hence 3P M165 would describe a plasmid clone # 3 containing the env insert 
derived from PBMC of cat M165.  
There were a few mutations observed among the viral variants from the three 
tissues, most of them being point mutations. The percentage identity (Clustal W 
program) of these sequences and their translated products was found to be between 97-
100% for all cats except cats A308 and M160 (Table 5). V3-V4 env sequences from cats 
A308 and M160 demonstrated greater amino acid variation as compared to the 
nucleotide sequence variation in their env sequence. The percentage identity of the  
 
 120
Table 5 
Variation in the V3-V4 envelope sequences obtained from tissues of six cats 
% identity with the original V3- 
V4 env sequence Cats Tissues 
 nucleic acid  amino acid  
M153 PBMC Not done Not done 
 Lymph nodes 98- 99% 97- 98% 
 Spleen 99- 100% 98- 100% 
M160 PBMC 99% 98% 
 Lymph nodes 97- 99% 91- 98% 
 Spleen 98- 99% 96- 98% 
M165 PBMC 98- 99% 97- 98% 
 Lymph nodes 99% 97- 100% 
 Spleen 99% 97- 99% 
M242 PBMC 98- 99% 98- 99% 
 Lymph nodes 98- 99% 97- 99% 
 Spleen 99% 97- 98% 
A306 PBMC 98- 99% 96- 99% 
 Lymph nodes 99% 98- 99% 
 Spleen 99% 98- 99% 
A308 PBMC 96- 99% 91- 98% 
 Lymph nodes 97- 98% 93- 97% 
  Spleen 97- 98% 91- 97% 
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translated products was between 91-98% for cat A308. For cat M160 the amino acid 
sequence of one of the clones derived from the lymph node (1L M160) was only 91% 
identical to the original FIV–PPR V3- V4 env sequence (Table 5).  
 Determinants reported for CRFK tropism include an E → K change at position 
407 and R at position 397 in the V3 region of the FIV env gene which is seen in the FIV-
Petaluma molecular clone 34TF10 but not in the FIV-PPR clone or the FIV-Petaluma 
clone FIV-14 (Table 6) and an E → K change at position 409 which is observed in both 
the Petaluma clones but not in the FIV-PPR clone (Table 6) (Verschoor et al., 1995). 
The FIV-PPR molecular clone has an E at position 407 (Phillips et al., 1990) and this 
was not changed in any of the clones examined. Clone 6P from cat M165 had a K → E 
change at position 397 while 3P from the same cat had an E → K change at position 409 
(Table 6). Clones 2S A308 and 5P A308 had a K → R change at position 397 (Table 6). 
Additionally, clones 4L from M160 and clone 1L from cat A306 had a replacement of E 
→ G and E → D, at position 409, respectively (Table 6). With the exception of E 
(hydrophilic) → G (amphiphilic) change for clone 4L M160, all the other amino acid 
changes were conserved with respect to the nature of the changed amino acid. However, 
since these changes were observed in only one of the three clones from the specific 
tissue, it is difficult to conclude on their relevance to the tropism of these viral variants.  
 Among the nine cysteine residues present in the V3-V4 region sequenced, seven 
cysteines were conserved in all the clones examined. Interestingly, two clones from the 
lymph nodes of two cats, A306 and A308 had C→ R alteration at position 366 while a 
C→ Y change at position 417 was seen in clones 7S A308 and 5L A306 (Table 7).  
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Table 6 
Mutations at sites involved in Crandell feline kindney cell tropism 
              V3- V4  Region of the FIV envelope gene 
 
Names of clones  Position 
397 
Position  
407           
Position  
409 
Tropism 
FIV-PPR 
 
K E E PBMC 
FIV- 34TF10 
(FIV- Petaluma 
clone) 
 
R K K CRFK 
FIV-14 (FIV- 
Petaluma clone) 
R E K CRFK, 
CXCR4 
tropic 
4L M160 K E  G*  
1L  A306 K E D Unknown 
3P M165 K E K Tropism  
6P M165 E E E  
2S A308 R E E  
5P A308 R E E  
* E (Hydrophilic) → G (Amphiphilic) change 
  
 
Table 7 
Change in cysteine residues 
Names of clones Mutation 
3L A308 C 366 R  
7S A308 C 417 Y  
2P A306 C 417 Y 
5L A306 C 366 R 
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Among the 8 potential N- linked glycosylation sites present in V3-V4 region sequenced, 
only 3 sites were completely conserved among all the clones examined (Table 8). 
Interestingly, clone #5 from the PBMC and clone # 2 from the spleen of cat A308 had 
point mutations at two potential N- linked glycosylation sites along with a change K→ R 
at position 397 (Tables 6 and 8). Clone # 2 from PBMC of cat A306 also had point 
mutations at two potential N- linked glycosylation sites along with a C→ Y change at 
position 417 (Tables 6 and 8). Both of these cats had been initially infected with virus 
250 TCID50 of the virus.  
Except for the clones mentioned above, all the remaining clones from the tissues 
of the six cats retained the original sequence as the parental FIV-PPR clone. 
 
Phylogenetic analysis 
 As demonstrated for other lentiviruses such as SIV, equine infectious anemia 
virus (EIAV) and caprine-arthritis encephalitis virus (CAEV) (Hotzel et al., 2002; 
Leroux et al., 1997; Zheng et al., 1997), the V3-V4 env region of the FIV-PPR strain in 
this study was assumed to have diverged from the parental FIV-PPR molecular clone 
used for infection, maybe resulting in tissue specific variants. Fig.16 A-F demonstrate 
unrooted phylogenetic trees of V3-V4 env nucleotide sequences from the tissues of six 
cats as compared to the V3-V4 nucleotide sequence of the parental FIV-PPR molecular 
clone. Contrary to our assumption, phylogenetic analysis of all the sequences for cats 
M153 (Fig. 16A), M160 (Fig. 16B) and M242 (Fig. 16D), indicated that for a single cat, 
the sequences derived from the PBMC, lymph node or spleen were similar enough to  
 
 124
Table 8 
Change in potential N-linked glycosylation sites 
Position and original 
sequence 
Changed sequence Variant name 
418- 420  NST NGT 7S M165 
 NIT 5P A308 
 NSA 2P A306 
 NSP 5S M242 
   
422- 424 NLT CONSERVED  
   
448- 450 NKS DKS 1S M242 
 DKS 2L M165 
 SKS 2P A306 
 KKS 5P A308 
 KKS 2L A308 
 KKS 1L M153 
 KKS 2S A308 
   
469- 471 NTS NAP 7P A306 
 NTL 2L M242 
   
481-483  NVS DVS 4L M153 
 KVS 4L M165 
 KVS 4P M160 
 NIS 5P M242 
 NAS 2S A308 
   
491-493  NCS CONSERVED  
   
518-520 NMT DMT 5L A306 
   
531- 533 NWS CONSERVED  
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 cluster together in the unrooted tree, without showing any tissue specific variants. For 
cat M165 (Fig. 16C), the sequences from the PBMC did cluster together (bootstrap 
value, 65%) whereas for cat A306 (Fig. 16E), the sequences from spleen clustered 
together (bootstrap value, 61%). However, these sequences were found to be 
approximately 98-99% identical with the original sequence (Table 5) when their amino 
acid sequences were compared. The V3-V4 env sequences from the tissues of cat A308 
(Fig. 16F) demonstrated more mutations, although no tissue specific variants were 
observed. 
  FIV-PPR belongs to clade A with an an overall nucleic acid sequence identity of 
91% and an env diversity of 14% as compared with the Petaluma strain from the same 
clade (Phillips et al., 1990). When the V3-V4 env nucleotide and amino acid sequences 
of representative clones for each tissue and each cat were compared to that of FIV-
Petaluma and FIV-PPR env sequences, using neighbor-joining method of computing 
divergence, all the sequences clustered together, with FIV-Petaluma being the outlier 
(Fig. 17 and 18). This shows that the viral env sequences from the three tissues remained 
relatively unchanged as compared to FIV-PPR even after three to six years p.i. 
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A. 
Fig. 16. Unrooted maximum-likelihood trees of V3-V4 envelope nucleotide sequences of viral variants 
from tissues of six FIV- PPR infected cats. Sequences from PBMC (designated as a hexagon), lymph node 
(designated as a rectangle) and spleen (designated as an oval) of cats M153 (Fig. 1A), M160 (Fig. 1B), 
M165 (Fig. 1C), M242 (Fig. 1D), A306 (Fig. 1E) and A308 (Fig. 1F) are shown. The number above each 
branch is the percentage of bootstrap replications supporting that branch. The single arrow points to the 
V3-V4 nucleotide sequence of the parental FIV-PPR clone. The viral isolates were assigned numbers 
composed of the number of the bacterial clone containing the env insert, followed by the letter indicating 
the organ from which the clones were obtained (L = lymph node, P = PBMC, S = spleen) followed by the 
name of the cat. 
4LM153
FIVPPR
3SM153
3LM153
6SM153
1LM153
5SM153
82
Bootstrap
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B. 
2LM160
FIVPPR
3PM160
2SM160
4LM160
6PM160
4PM160
4SM160
3SM160
1LM160
61
Bootstrap
 
Fig. 16. Continued 
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C. 
 
3PM165
5PM165
6PM165
3LM165
2SM165
4LM165
8SM165
FIVPPR
2LM165
7SM16565
61
51
Bootstrap
 
Fig. 16. Continued 
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D. 
3LM242
FIVPPR
3SM242
1LM242
1SM242
4PM242
5PM242
5SM242
2LM242
3PM242
65
63
Bootstrap
 
Fig. 16. Continued 
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E. 
2PA306
6SA306
5SA306
8SA306
FIVPPR
6LA306
7PA306
10PA306
5LA306
1LA306
63
61
Bootstrap
 
Fig. 16. Continued 
 
 
 
 131
F. 
 
2LA308
2SA308
5PA308
3LA308
7SA308
FIVPPR
2PA308
4PA308
3SA308
4LA308
90
76
84
64
62
Bootstrap
 
Fig. 16. Continued 
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Fig. 17. Neighbor-joining phylogenetic tree of V3-V4 envelope nucleotide sequences of viral variants
from lymph nodes, spleen and PBMC of six FIV-PPR infected cats. The single arrow points to the
parental FIV-PPR clone used to infect the cats while the double arrow points to an outlier, FIV-Petaluma
strain belonging to the same clade A as FIV-PPR. 
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Fig. 18. Neighbor-joining phylogenetic tree of V3-V4 envelope amino acid sequences of viral variants from
lymph nodes, spleen and PBMC of six FIV-PPR infected cats. The single arrow points to the parental FIV-
PPR clone used to infect the cats while the double arrow points to an outlier, FIV-Petaluma strain belonging
to the same clade A as FIV-PPR.  
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DISCUSSION 
  Unexpectedly, sequencing of the V3-V4 env region of provirus from PBMC, 
lymph nodes and spleen of cats infected with a molecular clone of FIV-PPR did not give 
rise to tissue specific viral variants. Surprisingly, our studies have demonstrated an 
almost uniform virus population in the three tissues examined from cats M153, M160, 
M165, M242 and A306. However, viral env sequences from the three tissues of cat 
A308 did demonstrate 7-9% divergence from the env sequence of the original FIV-PPR 
clone when the amino acid sequences were examined. In none of the groups was there 
any evidence of an accumulation of mutations over time leading to a change in the 
genotype of the quasispecies.  
 Genetic diversity arising as a result of evolving quasispecies or due to 
recombination between dually infected FIV strains has been reported (Bachmann et al., 
1997; Carpenter et al., 1998). Rigby et al. (1993) have suggested that positive selection 
for protein sequence changes operates in the variable region of FIV env gene. Although 
there has been a rapid increase in available FIV sequences particularly for the env gene, 
there have been very few studies focusing on the rate and nature of env sequence 
evolution within a single animal. The few studies reported were contradictory depending 
on the env region sequenced and whether the animals were naturally or experimentally 
infected. Phylogenetic studies based on sequencing the entire FIV env region by Sibelink 
et al. (1992) and sequencing the V3-V6 FIV env region by Nishimura et al. (1996), using 
tissues of naturally infected cats demonstrated more than 98% sequence similarity 
between the env viral sequences. Kohmoto et al. (2003) found that, the virus was 
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transmitted across the mucosal epithelium without broadening of cell tropism, after 
sequencing a 642-bp V3-V5 env region from PBMC of FIV-B-TM2 vaginally infected 
cats, at an early stage of infection (4 week p.i.). In another study, three of the six cats 
infected with FIV- 34TF10, one of the six cats infected with FIV-14 and two of the six 
cats infected with FIV-PPR clone were shown to be infected with variants in the bone 
marrow and lymphoid tissues identified by heteroduplex mobility assays (HMA) (Dean 
et al., 1999). However, phylogenetic analysis was not performed on the variants. In 
addition, Hosie et al. (2002), demonstrated emergence of 2 variant viruses with increased 
virulence in two of the three cats infected intraperitoneally with FIV-14. These virulent 
variant strains carried a mutation at position 409 in the env region (K →Q or K →E) that 
reduced the net charge of the V3 loop, reducing the ability of the env proteins to induce 
fusion in CXCR4 expressing cells. They have therefore, suggested that the E →K 
mutation at position 409 contributes to attenuation of the FIV-14 strain.  
In our study, clone # 3 from the PBMC of cat M165 did show an E →K mutation 
at position 409, which was found to be required for change of tropism to CRFK cells. 
However, there were no mutations associated with position 397 and 407 of the env V3 
region for the same clone. Based on studies by Hosie et al. (2002), it is possible that the 
E →K change in 3P M165 was associated with an attenuation of the virus virulence. 
However, since these changes were observed in only one of the three clones from the 
specific tissue, it is difficult to conclude on their relevance to the tropism or virulence of 
these viral variants.  
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 Our studies are in agreement with those of Kohmoto et al. (2003), in that there 
was no broadening of cell tropism associated with any of the FIV-PPR viral variants 
obtained from the three tissues, except for the clones mentioned in table 4A, whose 
tropism was unknown. Our studies were in contrast to those of Nishimura et al. (1996) in 
that the cysteines and the potential N-linked glycosylation sites in the V3-V4 region 
were not conserved among the viral variants obtained from the tissues of chronically 
infected cats. Our studies are also, in agreement with those of Siebelink et al. (1992) and 
Nishimura et al. (1996) in that the emerging variants in the tissues examined were very 
similar to the parental molecular clone used for initial infection. Overall, lack of 
variation in the FIV V3-V4 env region from tissues within each animal in our study was 
unexpected, considering that other lentivurses such as HIV, SIV, and caprine arthritis 
enteritis virus (CAEV) show variation in their env gene (Coffin, 1986; Hotzel et al., 
2002; Johnson et al., 1991; Leroux et al., 1997; Zheng et al., 1997). 
 In contrast, Greene et al. (1993) examined the in vivo evolution of FIV isolates 
obtained sequentially from a naturally and persistently FIV-infected cat over a 3-year 
period. Their results indicated that the variation in FIV was similar to the pattern and 
rate of variation found in other lentiviruses including HIV-1. Sequencing subgenomic 
regions of the FIV gag (p15/p24), polymerase (RT) and 5’ segment of the env gene 
coding for an N terminal region of gp120 spanning the first and second variable domains 
(V1-V2), they found that the major capsid protein and RT enzyme of polymerase were 
highly conserved as opposed to the env region which had relatively rapid and extensive 
variation in the order of 10-3 nucleotide substitutions/ site/ year, an order of magnitude 
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more than variation calculated for the gag and RT sequences (10-4 nucleotide 
substitutions/ site/ year). However, the V1-V2 FIV env region is located in the amino-
terminal leader and signal regions and is not present in the mature env protein due to 
proteolytic processing (Pancino et al., 1993b; Verschoor et al., 1993). The FIV V1-V2 
env region has also not been reported to be responsible for cellular tropism of FIV. 
Hence changes reported in that region might not be responsible for altering the 
pathogenicity of the variants.  
 Four of the six cats (cat A306, A308, M165 and M242) that were examined for 
the presence of variation in the V3-V4 env region, previously have demonstrated CD8+ 
T cell mediated non-cytolytic activity against FIV in vitro, described in chapter II (Choi 
et al., 2000b; Unpublished data from our laboratory). In vivo, such control of virus 
replication would lead to fewer mutations being incorporated in the virus due to limited 
viral replication cycles. This would also fail to drive the host immune responses to exert 
selective immune pressure that would contribute to the lack evolution of viral variants 
observed in our study. Moreover the SPF facility used to house the cats also might have 
reduced the selection pressure imposed by the host immune system on the virus. 
 The genetic diversity of the virus in the infected host arises from competition and 
selection among variants and results in altered cell tropism and replication efficiency. 
However, the level of genetic diversity of FIV genomes in infected cats is 2-fold lower 
than that of HIV-1 genomes in humans (Siebelink et al., 1992; Sodora et al., 1994). 
Additionally, a molecular clone of FIV–PPR was used for the initial infection of the six 
cats in our study, which eliminated effects of the initial diverse viral inoculum, 
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narrowing the biological phenotypes of virus available for persistence in the 
host. Moreover, the FIV-PPR molecular clone used in these studies was found to be 
minimally pathogenic after inoculation of SPF cats, as compared to the biological clone 
of FIV-PPR from which it was derived (Sparger et al., 1994). However, studies using 
pathogenic SIV molecular clones have demonstrated the presence of tissue specific 
variants (Buckner et al., 2002; Johnson et al., 1991) in the infected animals. Thus, lack 
of env V3-V4 variation observed in our studies reemphasizes the fact that presence of 
diversity and virulence of the initial virus inoculum is responsible for generating viral 
variants within the host.  
  HIV viral heterogeneity is correlated with both the length of the asymptomatic 
period following primary infection and to a slower CD4+ T cell decline (Delwart et al., 
1997; Wolinsky et al., 1996) with exceptions (Markham et al., 1998), while a relative 
stable evolutionary stasis of viral variants is associated with both rapid loss of CD4+ T 
cells and progression to AIDS. In our study, except for cat M165, all other cats had 
CD4+ T cell counts lesser than 200 cells/ul. Hence, lack of variation in the V3-V4 env 
region, in our study is therefore surprising, considering that the cats were long–term 
infected, showed signs of some clinical illness and immunosuppression. 
In conclusion, our results demonstrated an almost uniform population of viral 
variants from the three tissues of six cats chronically infected with the FIV-PPR 
molecular clone with no evidence of tissue specific variants.  
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CHAPTER VI 
 
SUMMARY AND DISCUSSION 
 
 The critical role of CD8+ cytotoxic T cells (CTLs) in the suppression of HIV has 
been suggested by the close relation between emergence of HIV specific CTL response 
and down regulation of viremia after acute infection, inverse correlation between the 
frequency of HIV-specific CTLS and levels of plasma load and the CD4+ T cell decline, 
the association of vigorous HIV-specific CTL response with slow progression of disease 
and the decline of HIV CTL activity with disease progression (Cohen and Fauci, 1996). 
However, in 1986, another type of antiviral activity against HIV was described that 
involved suppression of HIV replication by CD8+ T cells from asymptomatic, HIV 
infected individuals that did not involve killing the target cells (Walker et al., 1986). 
Subsequent studies have shown that one or more soluble molecule (s) secreted by CD8+ 
T lymphocytes mediate this non-cytolytic anti-viral activity (Copeland, 2002; Levy, 
2003; Moriuchi et al., 1996; Walker et al., 1986). Several groups also described a similar 
kind of antiviral activity for FIV, although the mechanisms of activation and conditions 
for viral suppression vary with the methodologies (Bucci et al., 1998a; Bucci et al., 
1998b; Choi et al., 2000b; Flynn et al., 1999; Flynn et al., 2002; Hohdatsu et al., 2000; 
Jeng et al., 1996). In our earlier studies, reproducible production of non-cytotoxic anti-
FIV activity from CD8+ T lymphocytes, from cats in the asymptomatic stage of FIV 
infection, was maximally achieved in vitro with effector cells stimulated by FIV-PPR 
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infected inducer T cells rather than mitogen (Choi et al., 2000b). However, most studies 
describing the CD8+ T cell non-cytolytic antiviral activity described, relied on mitogen 
(Concavalin A or phytohemagglutinin) stimulation of CD8+ T lymphocytes or stimulated 
CD8+ T lymphocytes using either anti-CD3 and anti-CD28 antibodies or a combination 
of the two antibodies. Thus, the use of inducer cells versus use of mitogen was the key 
difference between our studies and others. Although a number of reports have focused 
on identifying the molecules responsible for suppression of virus replication (HIV, FIV 
or SIV) in vitro (Blackbourn et al., 1994; Geiben-Lynn et al., 2001; Mosoian et al., 2000; 
Unpublished data from our laboratory) the physiologic stimulus required for the 
stimulation and induction of CD8+ T cells is not yet known. 
 The focus of this study was to examine various aspects related to the soluble anti-
FIV activity mediated by CD8+ T lymphocytes. This involved determining 1) the 
requirements for induction of CD8+ T cell mediated suppression of FIV replication, 2) 
the kinetics of the induction process, 3) phenotypes of the inducer T cells and 4) cross 
reactivity of the soluble CD8+ T cell mediated anti-FIV activity. Inducer cells used in 
our initial studies were irradiated FIV-infected T lymphocytes (Choi et al., 2000b). But 
immortalized FSF, transfected with SFV vector expressing either the FIV capsid or an 
irrelevant antigen, such as lacZ or FSF transfected with SFV vector expressing only its 
polymerase, could also mediate the induction process. The effector cells produced the 
soluble anti-FIV activity in the absence of MHC matched inducer cells when either FIV 
infected T cells or transfected FSF were used. Although MHC restriction was not 
required for the soluble anti-FIV response, it is not yet clear as to whether it might 
 
 141
improve or otherwise contribute to the activation of the effector cells in our system 
(Phadke et al., 2004).  Thus, it appeared that functional inducer cells did not need to be 
professional antigen presenting cells (APC) and these cells did not have to express the 
viable and complete virus. However, it would be worthwhile to determine if the use of 
professional APC such as dendritic cells or macrophages could serve to enhance the 
CD8+ T cell antiviral activity against FIV in our system, as has been reported for HIV 
(Barker et al., 1999; Castelli et al., 2003).  
 Our studies also showed that optimal induction of the suppressing activity 
generated by the effector cells occurred between days 1 to 4 and depended on cell-cell 
contact between inducer and effector cells (Phadke et al., 2004). This implicated a 
critical role for membrane antigen interactions in the communication between inducer 
and effector cells with cytokines playing an accessory or a separate role in the induction 
process. Cell-cell contact could depend on the interaction between costimulatory 
molecules and adhesion molecules (B7-1 (CD80), B7-2 (CD86), ICAM-1 or CD40) on 
the inducer cells with their respective ligands (CD28, CTLA-4, LFA-1 or CD40L) on the 
effector cells (Chirathaworn et al., 2002; Kochli et al., 1999; Kornbluth, 2002; Lenschow 
et al., 1996). 
 One of the important membrane molecules, that has been shown to play a role in 
enhancing the CD8+ T cell mediated suppression of HIV replication, is CD28 (Barker et 
al., 1997). CD28, through its interaction with the B7 family of proteins, B7-1 and B7-2, 
provides the major co stimulatory signal for augmenting and sustaining a T-cell response 
(Lenschow et al., 1996). In the case of HIV infection, CD8+ T cell antiviral factor 
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production has been found to be associated with cells expressing CD8, CD38, HLA-DR 
and CD28 (Jiang et al., 2003). Engagement of the CD28 molecule on CD8+ T cells from 
AIDS patients during stimulation in vitro restored and enhanced the ability of these cells 
to suppress HIV replication in vitro (Barker et al., 1997). Barker et al. (1999) also 
demonstrated that while both B7 molecules could deliver a costimulatory signal 
sufficient to increase CD8+ T cell antiviral activity, B7-2 on macrophages was found to 
enhance CD8+ T cell suppression of HIV replication in vitro.  
 In order to determine the membrane antigens that play a role in the induction 
process, modulations of phenotypes of freshly prepared PBMC were determined using a 
panel of feline antigen specific antibodies. Flow cytometry studies carried out on fresh 
PBMC from FIV infected and uninfected cats demonstrated a significant increase in the 
percentages of CD8+ T cells coexpressing the B7-1 co-stimulatory molecule in FIV 
infected cats as compared to the uninfected cats. The percentages of CD4+ T cells 
expressing B7-1 did not vary significantly with infection. There was no significant 
difference between the MHC class I and MHC class II expression on CD4+ T cells or 
CD8β+ T cells between FIV infected or FIV uninfected cats. Expression of B7-1 
costimulatory molecule on T cells was unusual since, normally these molecules are 
found on professional APC (Lenschow et al., 1996). However, a number of recent 
studies have shown that B7 molecules may be up regulated on T cells activated in vitro 
and on a subset of CD4+ and CD8+ T cells in HIV or FIV infection (Haffar et al., 1993; 
Kochli et al., 1999; Tompkins et al., 2002; Wyss-Coray et al., 1993b). Based on these 
observations and the flow cytomtery results discussed, it is possible that as with HIV 
 
 143
infection of humans, T cells in FIV infected cats developed an antigen presenting 
phenotype and hence contributed to the stimulation of effector CD8+ T cells in our 
system via B7-1 molecules. Blocking the costimulatory interactions between the inducer 
and effector cells would allow us to identify the exact molecules required for the 
induction process. However, lack of feline specific antibodies, such as feline CD28 
monoclonal antibody (Mab), feline CTLA-4 Mab and feline B7-2 Mab make such a 
study currently difficult. 
 An important feature of the FIV model system is the availability of molecular 
clones that, after transfection into cells in culture, give rise to infectious virions (Hosie et 
al., 2002; Miyazawa et al., 1991; Phillips et al., 1990; Siebelink et al., 1992; Talbott et 
al., 1989). The use of a molecularly cloned virus provides a unique opportunity to study 
both viral evolution within a host and to examine the generation of tissue specific 
variants by eliminating factors, such as a diverse inoculum of viral variants differing in 
their cellular tropism. However, infection of cats with a molecular clone of FIV (FIV-
PPR) did not give rise to tissue specific viral variant quasispecies in PBMC, lymph 
nodes and spleen tissues which were examined, based on sequencing of the V3-V4 
region of the envelope (env) gene. The variable V3-V4 FIV env region was chosen, 
since it has been found to include determinants required for FIV tropism (Siebelink et 
al., 1995b; Verschoor et al., 1995), to contain neutralization domains (de Ronde et al., 
1994; Lombardi et al., 1993b) and to undergo extensive mutations in other lentiviruses, 
such as HIV, SIV and caprine arthritis-encephalitis virus (CAEV) (Coffin, 1986; Endo et 
al., 2000; Hotzel et al., 2002; Johnson et al., 1991). Surprisingly, our studies have 
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demonstrated an almost uniform virus population in the 3 tissues examined for cats 
M153, M160, M165, M242 and A306. The diversity of the V3-V4 region did not 
increase, except in some clones from cats A308 and M160, but the variation seemed to 
be random.  
 One of the reasons for the emergence of tissue specific variants in HIV or SIV 
infections is the high replication rate of the virus, coupled with the rapid turnover of 
infected cells, lack of fidelity of the reverse transcriptase enzyme and selection of 
variants with envelope glycoprotein optimally adapted to locally expressed receptors on 
cells (Casado et al., 2001; Wong et al., 1997). However, there have been no studies 
supporting a high error rate associated with the FIV reverse transcriptase enzyme. 
Moreover, the CD8+ T cells of four of the six cats (cat A306, A308, M165 and M242) 
that were examined for the presence of variation in the V3-V4 region of the envelope 
gene in our study have in the past demonstrated CD8+ T cell mediated suppression of 
FIV replication in vitro [Choi et al., 2000b; Unpublished data from our laboratory]. 
Suppression of FIV-PPR virus in the PBMC in vitro would imply an in vivo ability of 
CD8+ T cells to suppress virus replication in infected cells. Suppression of virus 
replication would lead to a reduction in the number of mutations being incorporated in 
the virus due to fewer viral replication cycles. Since the suppressive activity of the CD8+ 
T cells blocked the viral replication in the cells, the cells could probably resume normal 
function with limited viral transmission. Since variation could also partly depend on the 
diversity of the initial inoculated population of virus, the use of a molecular clone of 
FIV-PPR could also be the reason for fewer mutations observed in the V3-V4 env region 
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in our studies. On the other hand, the molecular clone of FIV-PPR was prepared by 
transfection of a provirus plasmid into Crandell feline kidney cells (CRFK) and passage 
of virus stocks in PBMC cocultured with transfected CRFK cells. The molecular clone 
of FIV-PPR thus obtained was found to be minimally pathogenic after inoculation of 
SPF cats, as compared to the biological clone of FIV-PPR from which it was derived 
(Sparger et al., 1994). Thus, in vitro cultivation of FIV isolates may amplify less 
pathogenic variants within quasispecies that fail to drive the host immune responses of 
cats, to exert selective immune pressure that contributes to the evolution of viral 
variants. This may occur as a result of a favorable equilibrium being maintained between 
the infecting virus and the host, giving rise to a benign infection in the host. 
 Five distinct clades of FIV (A-E) have been identified with 15-30% variability in 
env amino acid sequence although a majority of viruses identified belong to either clade 
A or clade B (Bachmann et al., 1997; Elder et al., 1998; Sodora et al., 1994). Recent 
phylogenetic studies in our laboratory, using FIV isolates from naturally infected feral 
cats in Texas, have suggested that the Texas isolates seem to have evolved from FIV 
clade B and formed a distinct cluster as compared to other clades including clade B 
(Weaver et al., 2004). Experimental infection of cats with the FIV-TX53 strain which 
belongs to the newly emerging FIV subtype caused an acute disease characterized by 
viral dose dependent inversion of CD4+/ CD8+ T cell ratios that dropped below 1 by 11 
weeks p.i. This inversion of the CD4+/ CD8+ T cell ratio included a progressive decline 
in the CD4+ T cells in the infected cats accompanied by an increase in the CD8+ T cells, 
which was significant as compared to the CD8+ T cells in the uninfected cats only at the 
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highest dose administered. Additionally, the increase in the CD8+ T cells was 
characterized by an expansion of the CD8βlow population of CD8+ T cells. CD8βlow 
population of cells has been considered a marker for infection with more pathogenic 
strains of FIV, such as the molecular clone FIV-GL8414 or the pathogenic virus variants 
arising after FIV-PETF14 infection of cats (Hosie et al., 2002). There have been 
controversial reports demonstrating this population to be involved in the CD8+ T cell 
mediated in vitro suppression of various FIV strains, such as FIV-NCSU1 and FIV-GL8 
(Bucci et al., 1998b; Flynn et al., 2002; Hosie et al., 2002). Sequencing the variable 
region of the envelope gene from FIV-TX53 strains obtained from the cats infected with 
different doses of this virus should provide us information about possible emergence of 
new strains that coincide with the appearance of this population. Additionally, cell-
sorting studies could be carried out to determine whether the CD8βlow population or the 
CD8βhigh population of CD8+ T cells in the FIV-TX53 infected cats is responsible, for 
non-cytolytic suppression of the virus in vitro. 
 Earlier studies by Choi et al. (2000b) in our laboratory had demonstrated that 
supernatants collected from FIV-PPR infected cat PBMC (Clade A), which had been 
stimulated with irradiated FIV-PPR infected inducer T cells, suppressed viral replication 
of FIV-Petaluma (Clade A) infected target cells. Flynn et al. (1999) also demonstrated 
suppression of FIV-Petaluma strain and FIV-GL8 strain by mitogen stimulated 
lymphoblasts obtained from FIV-Petaluma infected cats. Again, both these strains 
belonged to FIV clade A. In contrast to these studies, we have now demonstrated that 
CD8+ T cells from FIV-PPR cats were able to suppress viral replication in PBMC 
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acutely infected with either FIV-TX53 or FIV-TX078 belonging to a new clade closely 
related to clade B. This is the first report of the soluble suppressing activity in FIV being 
cross-reactive among FIV clades. These studies were performed using inducer T cells to 
stimulate the CD8+ T effector cells, although we would predict the same results using 
FSF as inducer cells, as demonstrated in chapter II. 
 Earlier studies of CD8+ T cell antiviral activity against HIV have demonstrated 
lack of antigen-specificity both at the induction and effector phase. Thus, the fact that 
the CD8+ T cell antiviral response has been observed in asymptomatic HIV infected 
individuals, HIV exposed but uninfected individuals, healthy HIV-naïve individuals, as 
well as in FIV infected and uninfected cats (Bagasra and Pomerantz, 1993; Blackbourn 
et al., 1996; Brinchmann et al., 1990; Furci et al., 2002; Hsueh et al., 1994; Kootstra et 
al., 1997; Levy et al., 1998; Mackewicz et al., 1991; Rosok et al., 1997; Stranford et al., 
1999; Toso et al., 1995) suggests that mechanisms involved for the induction of this 
antiviral response are not virus specific. Lack of specificity at the effector phase has 
been demonstrated by Walker et al. (1991b), who showed that CD8+ T cells from an 
HIV-infected individual could suppress virus replication in CD4+ T cells acutely infected 
with HIV-1, HIV-2 or even SIVmac, thus demonstrating cross-reactivity.  
 Whole inactivated FIV-Petaluma vaccine was able to elicit CD8+ T cell antiviral 
activity in vaccinated cats, that suppressed FIV-Petaluma and FIV-GL8 virus replication 
in vitro (Flynn et al., 1999). Also, CD8+ T cells derived from macaques immunized with 
live, attenuated SIV have been shown to inhibit the replication of SIV via soluble factors 
in a non-MHC restricted manner (Gauduin et al., 1998). Moreover, studies in our 
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laboratory have also demonstrated suppression of feline leukemia virus (FeLV) 
replication in vitro by the supernatants of inducer T cell stimulated CD8+ T cells from 
FIV-PPR infected cats (Unpublished data from our laboratory). Thus the nonspecific 
nature of the soluble CD8+ T cell antiviral activity and that of induction indicates that 
CD8+ T cells, well characterized as providing adaptive immunity, can also provide innate 
immunity. This seemingly innate response of the cells to inhibit either FIV or HIV 
replication non-cytolytically may be due to the recognition by the effector CD8+ T cells 
of a “pathogen associated molecular pattern” (PAMP) on inducer cells or cells in close 
contact (Medzhitov and Janeway, 2000), making it a more general mechanism of control 
rather than being FIV specific. These PAMP could be highly conserved structures 
present on different pathogens (Medzhitov and Janeway, 2000). As the success of a FIV 
vaccine could be hampered by the occurrence of highly divergent viral variants in the 
field, the exploitation of this innate, soluble CD8+ T cell anti-FIV activity would be 
more useful. Hence, characterization and identification of the stimuli and mechanisms 
involved in the induction of the CD8+ T cell antiviral activity against FIV could provide 
information for strategies of practical exploitation of this innate T cell immunity and 
may contribute to the design of novel, safe and complementary anti-FIV therapeutic 
strategies. 
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